[{"_1":2,"_3":-5,"_4":-5},"loaderData",{"_5":6,"_7":8},"actionData","errors","root",{"_99":100},"en-item",{"_9":10,"_10":11},"kind","item",{"_12":13,"_14":15,"_16":17,"_18":19,"_20":21,"_22":23,"_24":25,"_26":27,"_28":29,"_30":31,"_32":31,"_33":34,"_35":36,"_37":38,"_39":40,"_41":42,"_43":44,"_45":46,"_47":-5,"_48":49,"_50":-5,"_51":-5,"_52":53,"_54":55,"_56":57,"_58":42,"_59":42,"_60":61,"_62":42,"_63":64},"id","kdnfefggrhvvfarspmivkt8yv","revision",2,"title","Onfolio Holdings提交S-1，拟登记出售股东转售最多105,223,881股普通股","originalTitle","Onfolio Holdings, Inc (0001825452) (Filer)","summary","Onfolio Holdings于2026年10月23日提交S-1注册声明，拟登记出售股东转售最多105,223,881股普通股；公司不会取得这些转售所得。根据为期24个月的融资安排，公司可酌情向出售股东发行最多1亿美元普通股，本次登记涉及其中价值5,500万美元的股份；融资所得须有25%用于购买加密货币作为储备资产，75%用于营运资金及一般公司用途。","reason","文件披露的融资安排可能带来股权稀释和加密货币储备配置风险；公司也仍面临纳斯达克股东权益合规要求。","source",{"_12":90,"_91":92,"_9":93,"_94":42,"_95":96,"_97":98},"links",{"_87":88,"_78":89},"publishedAt","2026-10-23T21:17:07.000Z","discoveredAt","2026-10-23T21:27:29.966Z","timelineAt","category","ai-products","tags",[84,85,86],"stockSymbols",[83],"score",66,"selected",true,"channel","news","story",{"_73":74,"_16":75},"x","readingMode","full","author","language","body",{"_64":77,"_78":-5,"_79":80,"_81":82},"outline",[],"relatedStories",[76],"indexable","markdownAvailable","group",{"_65":66,"_45":67,"_68":69,"_70":71,"_72":71},"hasTranslation","bodyLanguage","zh","factId","fauUK4Bnnkow",{"_73":74,"_16":75},"reportCount",1,"additionalSourceCount",0,"developmentCount","publicId","23ce91f5-65d2-4e55-b9e3-9fd03cc790b2","Onfolio拟登记股东转售逾1.05亿股并披露融资安排",{"_73":74,"_16":75},"

于2026年10月23日向美国证券交易委员会提交

注册编号 333-

美国

证券交易委员会

华盛顿特区 20549

S-1 表格

根据《1933年证券法》提交的注册声明

ONFOLIO HOLDINGS INC.

（注册人章程中指定的确切名称）

\n \n \n \n \n \n \n \n \n \n \n \n \n

特拉华州		7370		37-1978697
（注册成立或组织所在州或其他司法管辖区）		（主要标准工业分类代码）		（美国国税局雇主识别号码）

Dominic Wells
首席执行官

1007 North Orange Street, 4th Floor
Wilmington, Delaware 19801

(682)\n990-6920

（注册人主要执行办公室的地址（包括邮政编码）和电话号码（包括区号））

Northwest Registered Agent Service, Inc.

8 The Green, Ste B
Dover, Delaware 19901

302-581-4070

（送达代理人的姓名、地址（包括邮政编码）和电话号码（包括区号））

副本送至：

David M. Bovi, Esq.
David M. Bovi, P.A.

2855 PGA Blvd., Suite 150
Palm Beach Gardens, FL 33410

(561)\n655-0665

拟向公众出售的大致开始日期：本注册声明生效后，在切实可行的情况下尽快。

如果本表格所注册的任何证券拟根据《1933年证券法》第415条延迟或连续发行，请勾选以下方框。☒

如果本表格是根据《证券法》第462(b)条为发行注册额外证券而提交，请勾选以下方框，并列出同一发行先前生效的证券法注册声明编号。 ☐

如果本表格是根据《证券法》第462(c)条提交的生效后修正案，请勾选以下方框，并列出同一发行先前生效的证券法注册声明编号。 ☐

如果本表格是根据《证券法》第462(d)条提交的生效后修正案，请勾选以下方框，并列出同一发行先前生效的证券法注册声明编号。 ☐

请用勾选标记注明注册人是否为大型加速申报公司、加速申报公司、非加速申报公司、较小报告公司或新兴成长型公司。参见《交易法》第12b-2条中“大型加速申报公司”“加速申报公司”“较小报告公司”和“新兴成长型公司”的定义。

\n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n

大型加速申报公司	☐	加速申报公司	☐
非加速申报公司	☒	较小报告公司	☒
		新兴成长型公司	☒

如果是新兴成长型公司，请用勾选标记注明注册人是否已选择不采用《证券法》第7(a)(2)(B)条规定的、遵守任何新订或修订财务会计准则的延长过渡期。☐

注册人特此在可能需要的日期对本注册声明进行修订，以延迟其生效日期，直至注册人提交进一步修正案，明确声明本注册声明此后将根据经修订的《1933年证券法》第8(a)条生效；或直至本注册声明在证券交易委员会依据上述第8(a)条确定的日期生效。

本招股说明书中的信息尚不完整，且可能发生变更。在向美国证券交易委员会提交的注册声明生效之前，不得出售这些证券。本招股说明书不构成出售这些证券的要约，也不在不允许要约或出售这些证券的任何州征求购买这些证券的要约。

截至2026年10月23日，尚待完成

初步招股说明书

$\"\"$

ONFOLIO HOLDINGS INC.

出售股东发售的105,223,881股普通股

本招股说明书涉及本文所指的出售股东（“出售股东”）不时转售或以其他方式处置最多105,223,881股普通股，每股面值0.001美元（“普通股”），该等普通股由Onfolio Holdings Inc.（“公司”、“我们”或“我们的”）发行，其中包括：(i) 根据我们与出售股东于2026年4月10日签订的某项股权购买融资协议，我们可能向出售股东发行的最多5,500万美元普通股；根据该协议，在满足或豁免其中规定的条件后，公司有权但无义务不时自行决定向出售股东出售总额不超过1亿美元的新发行普通股（“融资安排”）。截至2026年10月20日，按假设发行价每股0.5227美元计算，该等股份为105,222,881股普通股；该价格为我们的普通股于2026年10月20日在纳斯达克股票市场有限责任公司（“纳斯达克”）的最后收盘价；以及(ii) 根据融资安排发行的1,000股普通股作为承诺费（“承诺股份”）。

我们在融资安排项下可发行的普通股实际数量将因当时向出售股东发行并出售的普通股市场价格而异。

本公司不会根据本招股说明书出售任何证券，也不会从出售股东转售或以其他方式处置我们普通股所得股份中获得任何收益；但是，我们可能从根据该融资安排向出售股东出售普通股中获得总额最高达 $100,000,000 的总收益，但须遵守该融资安排的条件，并假设我们登记了该融资安排下所有可发行普通股的转售。本公司将控制向出售股东出售普通股的时间和数量。根据该融资安排实际出售普通股将取决于本公司不时确定的各种因素，其中可能包括但不限于市场状况、普通股交易价格，以及本公司对其业务和运营需求适当资金来源的判断。本公司根据该融资安排获得的净收益将取决于本公司向出售股东出售普通股的频率和价格。本公司根据本公司与出售股东于 2026 年 4 月 10 日签订的特定登记权协议（“登记权协议”），登记出售股东不时根据该融资安排可能出售的普通股的转售或其他处置。根据登记权协议，为继续根据该融资安排发行和出售普通股，我们必须提交一份或多份额外登记声明，以登记转售根据该融资安排可发行的 45,000,000 股普通股；这些股份未根据本招股说明书及其组成部分的登记声明登记转售。

出售股东可以按照当时的市场价格或协商价格，通过公开交易或私人交易要约出售、出售或以其他方式处置正在登记的全部或部分普通股。与登记我们普通股有关的所有成本、费用和收费均由我们承担。根据本登记声明登记的普通股任何转售或其他处置的时间、频率和数量均由出售股东自行决定。就其根据该融资安排取得的普通股转售而言，出售股东可能被视为经修订的《1933 年证券法》第 2(a)(11) 条所指的“承销商”（“证券法”）。尽管出售股东有义务根据该融资安排的条款并受其条件和限制约束购买我们的普通股，但在我们选择向出售股东出售此类普通股的范围内（须遵守某些条件），我们无法保证会选择向出售股东出售任何普通股，也无法保证出售股东会根据本招股说明书出售其持有的任何或全部普通股。出售股东将承担与转售我们普通股有关的所有佣金和折扣（如有）。有关更多信息，请参阅本招股说明书第 20 页开始的“分销计划”。

我们是《证券法》第2(a)条所定义的“新兴成长型公司”，适用较低的上市公司报告要求。本招股说明书符合适用于新兴成长型公司发行人的要求。

我们的普通股和公开交易认股权证在 Nasdaq 上市并交易，代码分别为“ONFO”和“ONFOW”。2026年10月20日，我们普通股和公开交易认股权证在 Nasdaq 的收盘价/最后交易价分别约为$0.5227和$0.0111。

投资我们的证券涉及高度风险。有关投资我们的证券时应考虑的信息，请参阅本招股说明书第5页开始的“风险因素”。

您应仅依赖本招股说明书或其任何招股说明书补充文件或修订文件中包含的信息。我们未授权任何人向您提供不同的信息。

美国证券交易委员会或任何州证券委员会均未批准或否决这些证券，也未认定本招股说明书真实或完整。任何相反陈述均属刑事犯罪。

本招股说明书日期为2026年[●]。

\n\n \n \n \n\n\n\n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n

		页码
关于本招股说明书		ii
招股说明书摘要		1
发行		4
风险因素		5
关于前瞻性陈述的警示性声明		8
股权购买融资协议		10
所得款项用途		12
股息政策		12
发行价格的确定		12
出售股东		13
证券说明		14
分销计划		20
法律事项		23
专家		23
以引用方式纳入某些文件		23
您可以在哪里获取更多信息		24

您只能依赖本招股说明书中包含的信息或我们向您提及的信息。我们未授权任何人向您提供不同的信息。本招股说明书不构成出售本招股说明书所发行普通股以外任何证券的要约，也不构成购买该等证券的要约邀请。本招股说明书不构成在此类要约或要约邀请不合法的任何情况下出售任何普通股的要约，也不构成购买任何普通股的要约邀请。在任何情况下，本招股说明书的交付或与本招股说明书相关的任何出售均不得据此推断，自本招股说明书日期以来我们的事务未发生变化，或本招股说明书在其日期之后的任何时间仍然准确。

关于本招股说明书

我们通过引用方式将重要信息纳入本招股说明书。您可按照“您可以在哪里获取更多信息”一节中的说明，免费获取以引用方式纳入的信息。在决定投资我们的证券之前，您应仔细阅读本招股说明书以及“以引用方式纳入某些文件”一节所述的补充信息。

我们和出售股东均未授权任何人提供本招股说明书或我们编制或代表我们编制、或我们向您提及的任何自由撰写招股说明书中所载信息以外的任何信息，或作出其中所载陈述以外的任何陈述。对于他人可能向您提供的任何其他信息，我们不承担任何责任，也无法保证其可靠性。本招股说明书仅在合法的情形和司法管辖区内出售本招股说明书所发行的证券。本招股说明书或任何适用的自由撰写招股说明书所载信息仅截至其日期为最新信息，无论其交付时间或我们的证券出售时间如何。自该日期以来，我们的业务、财务状况、经营业绩和前景可能已经发生变化。

以引用方式纳入或在本招股说明书中提供的信息包含统计数据和估算，其中包括有关我们参与的市场规模和竞争地位的数据和估算，这些数据和估算来自我们的内部估算和研究，以及行业和一般出版物、第三方开展的研究、调查和研究。行业出版物、研究和调查通常会声明其数据来自被认为可靠的来源。尽管我们认为公司的内部研究可靠，且对我们市场和行业的定义恰当，但这些研究和定义均未经任何独立来源核实。

致美国境外投资者：我们和出售股东均未采取任何行动，以允许在美国以外任何需要采取此类行动的司法管辖区进行本次发行，或在该等司法管辖区持有或分发本招股说明书。在美国境外取得本招股说明书的人士必须自行了解并遵守有关在美国境外发行证券和分发本招股说明书的任何限制。

本招股说明书及以引用方式纳入本招股说明书的信息提及了我们的商标以及其他实体的商标。为方便起见，本招股说明书及以引用方式纳入本招股说明书的信息中提及的商标和商品名称（包括徽标、艺术作品和其他视觉展示）可能不会带有®或TM符号，但此类提及并不意味着我们不会在适用法律允许的最大范围内主张我们或相关许可方对这些商标和商品名称享有的权利。我们使用或展示其他公司的商品名称或商标，并不意味着与任何其他公司存在关联，或获得其认可或赞助。

招股说明书摘要

本摘要重点介绍本招股说明书其他部分所载的若干信息。由于本摘要仅为摘要，并未包含您在投资我们的普通股前应考虑的全部信息；本摘要的全部内容均受本招股说明书其他部分更详细信息的限制，并应与该等信息一并阅读。在决定投资我们的普通股前，您应仔细阅读整份招股说明书，包括从第 5 页开始的“风险因素”以及本招股说明书所载的财务报表及相关附注。

在本招股说明书中，除非另有说明，“本公司”“Onfolio”“我们”及“我们的”均指 Onfolio Holdings Inc. 及其子公司。

公司概况

我们收购在线企业的控股权益并积极管理这些企业。我们认为，这些企业：(i) 经营所在行业具有长期增长机会；(ii) 现金流为正且稳定；(iii) 面临的技术淘汰或竞争淘汰威胁极小；以及 (iv) 可由我们的现有团队管理，或已基本拥有强大的管理团队。通过收购并发展一组具备上述特征的多元化网站，我们相信可为投资我们股份的投资者提供分散自身投资组合风险的机会。

我们的长期目标是打造一家世界一流的控股公司，收购、运营并扩大盈利性在线企业。我们旨在通过卓越运营、明智的资本配置、强有力的领导层和基础设施，以及保持创新者和小企业主的心态来实现这一目标。

我们理想的收购对象具备以下特征：

\n\n

●

经验证的客户获取记录；

●

拥有让客户满意且具备品牌资产的产品，无论是实体产品还是数字产品；

●

增长趋势向上；

●

行业或领域不断发展；

●

收购价格具有吸引力；

●

尚未充分利用的营销资产或渠道；

●

热情高、价值高的受众群体或客户群；

●

利润率和现金流具有吸引力；以及

●

流量和收入来源多元化。

我们目前经营以下业务模式：D2C 电子商务、B2B SEO 和营销服务，以及 B2B 数字产品。我们预计将持续拓展这些垂直领域，同时提高我们在其中的市场份额。我们的商业模式并非围绕某个特定“细分市场”的成功，而是聚焦于在线营销发挥关键作用的特定垂直领域和媒介（在线营销既可作为相关企业自身的增长手段，也可作为这些企业提供的服务）。

本公司的全资子公司包括 Onfolio LLC、Vital Reaction, LLC、Mighty Deals LLC、Onfolio Assets, LLC、Onfolio Management, LLC、WP Folio, LLC、Proofread Anywhere, LLC、Contentellect, LLC、SEO Butler Limited、Pace Generative LLC 和 DealPipe, LLC。截至 2025 年 12 月 31 日，本公司还持有 DDS Rank, LLC、RevenueZen, LLC 和 Eastern Standard, LLC 的多数股权，分别持股 66%、88% 和 53%。

公司历史与信息

Onfolio Holdings, Inc. 于 2020 年 7 月 20 日根据特拉华州法律注册成立，旨在收购和发展高增长且盈利的互联网业务。公司主要通过在线业务的网站管理、广告和内容投放，以及某些网站的产品销售获得收入。我们拥有多家在线企业，并代表我们持有股权的某些未合并实体管理在线业务。公司分为两个业务部门：企业对企业（“B2B”）和企业对消费者（“B2C）。我们将位于 1007 North Orange Street, 4th Floor Wilmington, Delaware 19801 的办公场所视为主要行政办公室。电话号码为 (682) 990- 6920。

近期发展

修订章程细则

2026 年 9 月 29 日，公司董事会通过一致书面同意（代替召开会议）的方式，批准并通过了对公司《修订并重述的章程细则》第 2.07 条的修订。该章程细则最初于 2022 年 4 月 22 日通过，本次修订立即生效。该修订将股东会议的法定人数要求从亲自出席或委托代理人出席、且所持股份拥有公司有权在会议上投票股份多数表决权，降低为亲自出席或委托代理人出席、且所持股份拥有该等股份三分之一（1/3）表决权。

反向股票拆分

2026 年 8 月 10 日，公司根据股东在 2026 年 4 月 6 日召开的特别股东大会上批准的授权，对已发行和流通的普通股实施了 1 比 50 的反向股票拆分。公司获准发行的股票总数仍为 305,000,000 股，包括 (i) 300,000,000 股普通股，每股面值 $0.001；以及 (ii) 5,000,000 股优先股，面值 $0.001，其中 1,000,000 股优先股仍指定为 A 系列优先股。反向股票拆分未发行零碎股；零碎股向上取整至最接近的整数股。公司未偿还股权奖励、认股权证和可转换票据相关的股份数量，以及适用的行权价和转换价格均按比例调整。除非另有说明，公司截至 2026 年 6 月 30 日的合并财务报表及其附注中的所有股数和每股金额均已追溯调整，以反映所有列报期间的反向股票拆分。

纳斯达克上市资格通知——2026 年 5 月

2026年5月26日，我们收到纳斯达克上市资格部的书面通知（以下简称“2026年5月通知”），告知我们未遵守纳斯达克上市规则5550(b)(1)。该规则要求在纳斯达克资本市场持续上市的公司维持至少2,500,000美元的股东权益。2026年5月通知指出，公司截至2026年3月31日的财政季度的Form 10-Q季度报告披露股东权益为1,216,603美元。截至2026年5月通知日期，公司也不符合以下替代持续上市标准：(i) 上市证券市值达到35百万美元；或(ii) 最近一个已完成财政年度或最近三个已完成财政年度中的两个年度持续经营净收益达到500,000美元。根据纳斯达克规则，公司须在2026年5月通知日期起45个日历日内（即截至2026年7月10日）提交恢复合规计划。如果计划获接受，纳斯达克可自2026年5月通知日期起给予最多180个日历日的延期，以证明符合股东权益要求。公司已在规定的45日期限内及时向纳斯达克提交合规计划。纳斯达克在2026年10月5日的信函（以下简称“2026年10月信函”）中，在审阅公司的合规材料后，批准公司将恢复遵守纳斯达克上市规则5550(b)的期限延长至2026年11月23日。根据延期条款，我们必须在2026年11月23日前恢复合规，并按照信函中规定的要求，向美国证券交易委员会和纳斯达克提交一份证明合规的Form 8-K当前报告。纳斯达克将继续监督公司持续合规情况。2026年10月信函规定，如果公司提交截至2026年12月31日止年度的Form 10-K年度报告时仍未能证明合规，公司可能面临退市。若公司未能满足延期条款，纳斯达克工作人员将发出书面退市通知，公司可向纳斯达克听证委员会提出上诉。2026年5月通知、2026年10月信函以及公司的不合规状况均不会立即影响普通股在纳斯达克资本市场的上市或交易，也不会影响公司的业务、运营或向美国证券交易委员会履行报告义务。无法保证公司能够在延期期间恢复合规或继续符合纳斯达克的持续上市要求。

股东年会

2026年8月6日，我们召开了年度股东大会，股东在会上：(i) 选举了四（4）名董事会候选人；(ii) 批准聘请 Astra Audit & Advisory, LLC 担任我们截至2026年12月31日的财年的独立注册会计师事务所；(iii) 根据 Nasdaq 市场规则 5635(d)，批准可能发行超过我们已发行流通普通股 19.99% 的股份，该等股份依据该融资安排发行，且每股价格低于适用 Nasdaq 规则所定义的“最低价格”；以及 (iv) 批准修订公司注册证书，将普通股授权股数从300,000,000股增加至600,000,000股。截至本招股说明书日期，将普通股授权股数从300,000,000股增加至600,000,000股的公司注册证书修订案尚未提交至特拉华州州务卿。

作为较小报告公司的影响

作为一家较小报告公司，我们有资格豁免适用于其他非较小报告公司的上市公司的各项报告要求，包括但不限于：

●

在定期报告、委托书和注册声明中减少披露义务（例如有关高管薪酬的事项）；以及

●

无需遵守《2002年萨班斯-奥克斯利法案》（“萨班斯-奥克斯利法案”）第404(b)条的审计师鉴证要求。

我们将保持较小报告公司身份，直至以下任一条件满足之财政年度结束：(i) 我们的公众普通股流通市值超过2.5亿美元；或 (ii) 我们最近一个已完成财年的年收入超过1亿美元，且我们的公众普通股流通市值或公众流通市值超过7亿美元。如果我们成为投资公司、资产支持发行人，或成为非较小报告公司母公司的多数控股子公司，我们也将不再符合较小报告公司身份。

我们已选择在本招股说明书所属的注册声明中采用部分减少披露义务，并可能在未来提交的文件中选择采用其他减少报告要求。因此，我们向股东提供的信息可能不同于您从其他持有其股权的上市报告公司所获得的信息。

作为新兴成长型公司的影响

我们符合联邦证券法所定义的“新兴成长型公司”资格。只要我们仍是新兴成长型公司，就无需遵守适用于其他非“新兴成长型公司”上市公司的要求，包括但不限于，无需遵守《萨班斯-奥克斯利法案》第404条的审计师鉴证要求、定期报告和委托书中有关高管薪酬的简化披露义务，以及免于就高管薪酬举行无约束力的咨询性投票和就此前未经批准的任何金色降落伞付款取得股东批准的要求。我们打算利用这些报告豁免，直至不再属于新兴成长型公司。

本次发行完成后，我们将继续符合新兴成长型公司的资格，直至以下最早发生的日期：(1) 我们年度总收入达到至少 $1.235 billion（按通胀调整）的财政年度最后一天；(2) 我们首次公开募股日期五周年之后的财政年度最后一天；(3) 在此前三年期间，我们发行超过 $1.235 billion 不可转换债务之日；以及 (4) 我们被视为《经修订的1934年证券交易法》（“《交易法》”）所定义的“大型加速申报公司”之日。我们已选择根据《JOBS法案》第102(b)(2)条采用延长过渡期，以遵守新的或修订后的会计准则；该条款允许我们延迟采用对上市公司和非上市公司规定了不同生效日期的新会计准则或修订后的会计准则，直至这些准则适用于非上市公司。由于作出这一选择，我们的财务报表可能无法与遵守上市公司生效日期的公司进行比较。

发行概况

\n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n

发行人	Onfolio Holdings, Inc.

出售股东发售的证券	最多 105,223,881 股普通股，包括 (i) $55.0 million 股普通股，截至 2026年10月20日，按假设发行价每股 $0.5227 计算，相当于 105,222,881 股普通股；该发行价为普通股于 2026年10月20日的收盘价；以及 (ii) 我们向出售股东发行的 1,000 股普通股，作为承诺股。

本次发行的条款	出售股东（包括其受让人、受赠人、质权人、受让方及权益继承人）可不时在 Nasdaq Capital Market 或普通股上市交易的任何其他证券交易所、市场或交易场所，或通过私下交易，出售、转让或以其他方式处置本招股说明书所发售的任何或全部普通股。普通股可按固定价格、出售时的现行市场价格、与现行市场价格相关的价格或协商价格出售。

本次发行后发行在外的普通股(1)	最多 107,723,129 股普通股，假设 (i) 发行全部 105,223,881 股普通股，且 (ii) 我们不再发行其他普通股。实际发行的股份数量将根据本次发行中的销售价格而有所不同。

所得款项用途	根据本招股说明书，出售股东出售普通股所得款项，我们一概不会收到。招股说明书构成其一部分的注册声明生效后，我们可能通过融资安排，从我们根据该融资安排向出售股东出售的普通股中获得最高总额为 $100,000,000 的总收益；前提是我们出售融资安排项下有权（但无义务）向出售股东出售的全部普通股，且遵守融资安排的其他条件。

股息政策	本公司从未就普通股宣派现金股息。我们目前打算将所有可用资金及未来收益用于为业务增长提供资金，并履行 A 系列优先股的股息义务。我们预计在可预见的未来不会就普通股支付任何现金股息。有关股息政策的更多信息，请参阅本招股说明书中的“股息政策”和“风险因素——持有我们证券相关的风险”。

交易代码	我们的普通股和公开交易认股权证分别在纳斯达克资本市场上市，交易代码为“ONFO”和“ONFOW”。

风险因素	在决定是否投资普通股之前，您应仔细考虑本招股说明书所载信息，以及本文所列并以引用方式纳入的“风险因素”中具体列出的因素。

(1)

本次发行后发行在外的普通股总数以截至 October 23, 2026 发行在外的 2,499,248 股普通股为基础。除非另有说明，本次发行后发行在外的股份不包括以下股份：

\n\n

●

已发行在外、可购买最多 138,714 股普通股的认股权证，加权平均行权价为每股 $126.79；以及

\n\n

●

发行在外、可购买最多 15,715 股普通股的期权，加权平均行权价为每股 $48.31。

风险因素

在购买任何证券之前，您应仔细考虑以引用方式纳入本招股说明书的风险因素，这些因素载于我们的 Form 10-K 年度报告，以及我们的 Form 10-Q 季度报告和 Form 8-K 当前报告中所述的任何后续更新。有关这些报告和文件的说明以及查阅方式，请参阅“其他信息”和“以引用方式纳入的某些信息”。我们目前未知或目前认为无关紧要的其他风险，之后可能会对我们的财务状况、经营业绩、业务和前景造成重大不利影响。

除以引用方式纳入本文的风险因素外，公司还发现以下可能影响我们业务的不确定性和风险因素：

与本次发行相关的风险

我们向出售股东出售普通股可能会稀释现有股东的权益，而出售股东随后出售其购得的普通股，或市场认为此类出售可能发生，都可能导致我们普通股的价格下跌。

2026年4月10日，我们与出售股东签订了融资安排，出售股东据此承诺购买最多100,000,000美元的普通股。在24个月期间内，自融资安排所列条件得到满足之日起（包括本招股说明书组成部分的注册声明经SEC宣布生效），我们可自行决定不时根据融资安排向出售股东发行并出售股份。我们根据融资安排可向出售股东发行并出售的股份，其购买价格将根据我们启动出售时普通股的价格而有所不同。视当时的市场流动性而定，此类股份的出售可能导致我们普通股的交易价格下跌。

我们通常有权控制未来向出售股东出售股份的时间和数量。我们根据融资安排向出售股东出售普通股（如有），将取决于市场状况及我们决定的其他因素。我们最终可能决定向出售股东出售融资安排项下可供出售的普通股的全部、部分或不出售任何股份。如果我们向出售股东出售股份，出售股东购得股份后，可自行决定随时或不时转售全部、部分或不转售这些股份。因此，我们向出售股东出售股份可能会大幅稀释其他普通股持有人的权益。此外，向出售股东出售大量普通股，或市场预期将进行此类出售，可能使我们未来更难在我们原本希望的时间和价格发行股权或与股权相关的证券。

无法预测我们根据融资安排可能向出售股东出售的普通股实际数量，也无法预测此类出售所得的实际总额。

由于我们可选择根据该融资安排向出售股东出售普通股（如有）的每股购买价格，将根据我们选择根据该融资安排向出售股东出售股份时普通股的市场价格而波动，因此截至本招股说明书日期且在任何此类出售之前，我们无法预测我们将根据该融资安排向出售股东出售的普通股数量、出售股东根据该融资安排购买我们股份时将支付的每股购买价格，或我们将从出售股东根据该融资安排进行的购买中获得的总收益。根据该融资安排，我们已同意从正式授权的股本中预留并登记不少于根据该融资安排可发行普通股的100%，计算时假定每股价格等于以下两者中较低者的80%：(i) 测算日前三（3）日的VWAP和(ii) 普通股每股最近收盘价（“预留估算值”）。

我们可能无法获得与出售股东之间融资安排项下的全部可用金额。我们可能需要额外融资以维持运营，否则我们可能无法继续运营，且后续融资的条款可能对我们的股东产生不利影响。

我们根据本招股说明书登记了价值$55,000,000的普通股。在24个月期间内，我们可不时指示出售股东根据融资安排通过“常规购买”购买最多$100,000,000的普通股，购买数量通常会根据出售时我们普通股的收盘售价而有所不同。此外，在融资安排规定的某些情况下，我们也可自行决定指示出售股东按融资安排规定通过“加速购买”购买额外普通股。

根据我们普通股当时的市场价格，我们可能无法在融资安排期限内向出售股东出售总额达$100,000,000的股份。如果出售将导致出售股东实益拥有的我们普通股超过融资安排中更详细说明的持股上限，出售股东将无需购买任何我们的普通股。在没有其他融资来源的情况下，我们无法获得融资安排项下部分或全部可用金额，可能会对我们的业务产生重大不利影响。

我们在多大程度上依赖出售股东作为资金来源，将取决于多项因素，包括我们普通股当时的市场价格以及我们能否从其他来源筹集资金。如果无法从出售股东处获得足够资金，或获得资金会造成过度稀释，我们将需要寻找其他资金来源以满足营运资金需求。即使我们根据融资安排向出售股东出售了全部$100,000,000的普通股，我们仍可能需要筹集额外资金，以继续为运营提供资金并执行当前业务战略。

在不同时间买入股票的投资者可能会支付不同的价格，而出售卖出股东所持有的普通股可能导致我们的普通股价格下跌。

根据该融资安排，在市场需求允许的情况下，我们有权决定向卖出股东出售股票的时间、价格和数量。如果我们选择根据该融资安排向卖出股东出售我们的普通股，卖出股东取得这些股票后，可自行决定随时或不时以不同价格转售全部、部分或不转售任何此类股票。因此，在本次发行中不同时间从卖出股东处购买股票的投资者可能会支付不同的价格，因而可能面临不同程度的稀释，在某些情况下还会遭受重大稀释，并取得不同的投资结果。由于我们未来可能以低于投资者在本次发行中购买股票时所付价格向卖出股东出售股票，投资者从卖出股东处购买的股票价值可能下跌。此外，卖出股东出售大量我们的普通股，或市场预期其将进行此类出售，可能导致我们普通股的交易价格下跌，或使我们在未来难以按原本期望的时间和价格出售股权或股权相关证券。

我们的管理层将对向卖出股东出售普通股所得净款项（如有）的用途拥有广泛的酌情决定权；您可能不同意我们对所得款项的使用方式，且所得款项可能无法得到有效利用。

本招股说明书涉及卖出股东可能不时发售和出售的我们的普通股。卖出股东出售股票时，我们不会获得任何所得款项。不过，我们可能从根据该融资安排向卖出股东出售股票中获得最高 $100,000,000 的总收入。根据该融资安排向卖出股东出售我们的普通股所得净款项的预期用途，反映了我们基于当前计划和业务状况的意向。根据该融资安排，任何普通股出售所得款项必须由公司按以下方式使用：(i) 百分之二十五 (25%) 用于购买加密货币作为储备资产；(ii) 其余百分之七十五 (75%) 用于营运资金和一般公司用途，但不得将任何所得款项用于偿还向公司或任何子公司的高管或员工提供的任何垫款或贷款，或支付任何关联方义务。

我们根据该融资安排出售普通股所得净款项的百分之二十五（25%）必须用于购买加密货币，作为储备资产。加密货币是高度波动的资产，其市场价值可能在短期内因多种因素大幅波动，包括但不限于市场情绪、监管动态、技术变化和宏观经济趋势。因此，公司使用根据该融资安排出售普通股所得净款项购买的任何加密货币（如有）都可能大幅贬值，这可能对公司的财务状况和市场认知产生不利影响。将资金配置于加密货币，而非创收业务或传统储备，可能限制公司的流动性，降低其为营运资金或战略举措提供资金的能力，并增加其遭受宏观经济冲击的风险。

我们根据该融资安排出售普通股所得净款项的百分之七十五（75%）必须用于营运资金和一般公司用途。由于管理层有广泛酌情权，可决定将该融资安排下出售股份所得净款项中的多少用于营运资金和一般公司用途，您将依赖管理层对该等净款项用途的判断，并且在作出投资决策时，您将没有机会评估这些款项是否得到恰当、有效或高效的使用。在这些款项使用之前，我们可能会以无法为我们带来有利回报甚至任何回报的方式进行投资。此外，管理层可能将净款项用于无法改善我们业务、财务状况或市场价值的公司用途。管理层未能恰当、有效或高效地使用这些资金，可能对我们的业务、财务状况、经营业绩和现金流产生重大不利影响。

出售股东和/或我们现有证券持有人在公开市场上出售大量证券，可能导致我们的普通股价格下跌。

出售股东可根据本招股说明书出售最多55,000,000美元的普通股。假设以每股0.5227美元的价格出售105,222,881股普通股，该等股份将约占我们已发行在外普通股的97.67%。出售股东和/或我们的其他现有证券持有人在公开市场上出售大量普通股，或市场认为此类出售可能发生，都可能压低我们的普通股和认股权证的市场价格，并可能削弱我们通过出售额外股权证券筹集资金的能力。我们无法预测此类出售可能对普通股和认股权证的现行市场价格产生何种影响。

我们可能无法继续在 Nasdaq 维持普通股和公开交易认股权证的上市。目前，我们不符合 Nasdaq 的最低股东权益要求，这意味着我们的普通股可能被摘牌，从而可能对普通股的流动性和市场价值产生重大不利影响。

尽管我们的普通股和公开交易认股权证在 Nasdaq 上市，但我们必须满足某些财务和流动性标准，才能维持上市。如果我们继续违反 Nasdaq 的上市要求，或继续未能满足 Nasdaq 的任何上市标准，我们的普通股和公开交易认股权证可能被摘牌。此外，我们的董事会可能认定，在全国性证券交易所维持上市的成本超过其收益。我们的普通股和公开交易认股权证从 Nasdaq 摘牌，可能严重影响股东买卖普通股和公开交易认股权证的能力，并可能对普通股和认股权证的市场价格及其交易市场的效率产生不利影响。普通股和公开交易认股权证被摘牌，可能严重削弱我们的融资能力，并损害您的投资价值。

根据纳斯达克上市资格部于2026年5月发出的通知，纳斯达克告知我们未遵守纳斯达克上市规则第5550(b)(1)条。该规则要求在纳斯达克资本市场持续上市的公司至少维持2,500,000美元的股东权益。2026年5月通知指出，公司截至2026年3月31日的财政季度的10-Q表季度报告显示，股东权益为1,216,603美元。截至2026年5月通知发出之日，公司也未达到以下替代持续上市标准：(i) 上市证券市值达到3,500万美元；或 (ii) 最近一个已完成财政年度或最近三个已完成财政年度中的两个年度，持续经营业务净收入达到500,000美元。根据纳斯达克规则，公司须在2026年5月通知发出之日起45个日历日内（即截至2026年7月10日）提交恢复合规计划。如果该计划获接受，纳斯达克可从2026年5月通知发出之日起给予最长180个日历日的延期，以证明公司符合股东权益要求。公司已在规定的45日期限内及时向纳斯达克提交合规计划。纳斯达克审查了公司的合规材料后，在2026年10月函中批准公司延期至2026年11月23日，以恢复遵守纳斯达克上市规则第5550(b)条。根据延期条款，我们必须在2026年11月23日前恢复合规，并按照函中规定的要求向美国证券交易委员会和纳斯达克提交当前报告（8-K表），以证明合规。纳斯达克将继续监控公司的持续合规情况。2026年10月函规定，如果公司在提交截至2026年12月31日止年度的10-K表年度报告时仍未能证明合规，可能会被摘牌。如果公司未满足延期条款，纳斯达克工作人员将发出书面摘牌通知，公司可向纳斯达克听证委员会提出申诉。2026年5月通知、2026年10月函以及公司的不合规状况，均不会立即影响普通股在纳斯达克资本市场的上市或交易，也不会影响公司的业务、运营或向美国证券交易委员会履行报告义务。无法保证公司能在延期期间恢复合规，或继续符合纳斯达克的持续上市要求。

关于前瞻性陈述的警示性声明

本招股说明书包含前瞻性陈述。前瞻性陈述涉及风险和不确定性，例如有关我们计划、目标、预期、假设或未来事件的陈述。在某些情况下，您可以通过“预计”“估计”“计划”“预计”“持续”“正在进行”“预期”“我们相信”“我们打算”“可能”“应该”“将”“能够”等术语及其他表示不确定性或未来可能、将会或预计发生某项行动的类似表达来识别前瞻性陈述。这些陈述涉及估计、假设、已知和未知的风险、不确定性及其他因素，这些因素可能导致实际结果与前瞻性陈述中明示或暗示的任何未来结果、业绩或成就存在重大差异。您不应过度依赖这些前瞻性陈述。

前瞻性陈述的示例包括但不限于：

\n\n

●

未来产品开发的预计时间；

\n\n

●

成本、收入、收益、资本结构及其他财务项目的预测；

\n\n

●

有关我们计划和目标的陈述；

\n\n

●

有关我们业务运营能力的陈述；

\n\n

●

有关预期未来经济表现的陈述；

\n\n

●

有关我们市场竞争情况的陈述；以及

\n\n

●

有关我们或我们业务的陈述所依据的假设。

前瞻性陈述既非历史事实，也不代表对未来业绩的保证。相反，这些陈述仅基于我们对业务未来、未来计划和战略、预测、预期事件和趋势、经济及其他未来状况的当前信念、预期和假设。由于前瞻性陈述涉及未来，因此会受到固有的不确定性、风险以及难以预测且许多超出我们控制范围的情况变化的影响。我们的实际业绩和财务状况可能与前瞻性陈述所示存在重大差异。因此，您不应依赖任何此类前瞻性陈述。可能导致我们的实际业绩和财务状况与前瞻性陈述所示存在重大差异的重要因素包括但不限于以下因素：

\n\n

●

我们管理当前及预计财务状况和估计现金消耗率的能力，包括我们对支出、未来收入和资本需求的估计，以及最终持续经营的能力；

●

我们筹集额外资本以进一步发展和拓展业务、实现长期业务目标的能力。我们的收入有限，且无法预测何时才能实现显著收入并持续盈利；

●

我们实现显著收入并持续盈利的能力；

●

商誉和长期资产减值

●

客户需求变化；

●

我们以具有成本效益的方式打造品牌、吸引新客户并以具有成本效益的方式留住客户的能力；

●

我们在参与线上业务的市场中保持竞争力的能力；

●

我们采取战略行动（包括收购和处置）以及成功整合所收购业务的能力；

●

我们继续成功地将线上业务作为一个整体进行管理的能力；

●

我们获得融资额度下可用部分或全部金额的能力；

●

信息技术系统发生安全漏洞、网络攻击及其他重大中断；

●

法律法规的发展和变化，包括通过立法行动以及修订规则和标准加强对本行业的监管；

●

我们的市场地位和市场状况，包括政府政策、关税和贸易壁垒的影响；

●

发生战争和/或其他敌对行动、政治不稳定或灾难性事件；

●

严重天气、火灾、洪水和地震等自然事件，或对我们的运营系统、设施或设备造成的人为或其他干扰；

●

与环境、社会和治理（ESG）事项相关的风险及成本，包括相关规则制定活动的范围和进度；

●

本公司面临的其他风险；

●

本公司无法控制的其他因素；以及

●

本文件“风险因素”部分以及本公司随后向美国证券交易委员会（SEC）提交并可在其网站 www.sec.gov 上查阅的任何报告中所述的其他因素和风险。

我们在本招股说明书中作出的任何前瞻性陈述仅基于我们目前可获得的信息，且仅反映作出该陈述之日的情况。无论是因新信息、未来发展还是其他原因，我们均不承担公开更新不时作出的任何书面或口头前瞻性陈述的义务。

股权购买融资协议

2026年4月10日，本公司与出售股东签订了融资协议。根据融资安排，本公司有权（但无义务）在融资期限内，由本公司全权酌情决定，不时向出售股东出售总额最高达1亿美元的新发行本公司普通股。

公司必须将通过融资安排出售任何普通股所得款项用于以下用途：(i) 25% 用于购买加密货币，作为储备资产；(ii) 其余 75% 用于营运资金及一般公司用途；但所得款项不得用于偿还向公司或其任何子公司的高管或员工提供的任何垫款或贷款，也不得用于支付任何关联方义务。

自融资安排生效之日起至融资安排终止之日止，在每个预付款通知日（定义见融资安排），且满足或豁免融资安排中规定的各项先决条件的前提下，公司可通过一次或多次预付款（各称为“预付款”）根据融资安排出售普通股。公司须向出售股东送达通知（各称为“预付款通知”）以发起预付款。根据任何预付款通知发行的每股购买价格，将以指定定价期间内普通股的市场价格减去协商折扣为基础，并依照客观、预先确定的公式计算，具体内容详见融资安排。对于融资安排中定义的常规购买，购买价格为以下两者中较低者的 97%：(i) 定价期间内最低的每小时 VWAP（定义见融资安排）；(ii) 定价期间内最低成交价。对于融资安排中定义的加速购买和延长购买，购买价格为以下两者中较低者的 98%：(i) 定价期间内最低的每小时 VWAP；(ii) 定价期间交易日内的最低成交价。

There\nis no mandatory minimum number of shares that may be sold in any Advance, provided that each requested Advance may not exceed the Maximum\nAdvance Amount, as defined in the Facility, and each Advance is subject to certain limitations described in the Facility, including,\nbut not limited to, limitations based on (i) the trading volume of the Common Stock during the applicable Pricing Period, as defined\nin the Facility; (ii) the Ownership Limitation, and (iii) the remaining availability under the $100 million commitment.

The\nCompany is not obligated to make sales of Common Stock under the Facility to the Selling Stockholder and there are no minimum draw requirements,\ncommitment fees (other than described below), or penalties for non-use. The Selling Stockholder has no right to require the Company to\ninitiate any Advance.

As\nconsideration for the Selling Stockholder’s commitment to purchase shares of Common Stock in accordance with the Facility, the\nCompany paid a commitment fee by issuing the Commitment Shares.

Additionally,\nthe Company will be prohibited from conducting any Variable Rate Transactions, as defined in the Facility, from the date of the Facility\nuntil the earlier of (i) 12 months after the date on which the registration statement, which this prospectus is a part of, is declared\neffective by the Securities and Exchange Commission, and (ii) three (3) months after the termination date of the Facility.

In\naddition, at any time during the Additional Issuance Restricted Period, as defined in the Facility, the Company may not, directly or\nindirectly, effect any Subsequent Placement, as defined in the Facility, without first, offering such opportunity to the Selling Stockholder\nto provide such capital or financing to the Company on the same or similar terms as the respective third party’s terms, and the\nSelling Stockholder may in its sole discretion determine whether the Selling Stockholder will provide such capital or financing for such\nSubsequent Placement.

The\nFacility also contains customary representations, warranties, covenants, conditions to each Advance, and termination provisions. The\nterm of the Facility is 24 months from the date of the Facility and may be terminated upon the occurrence of specified events, including\nthe exhaustion of the commitment amount or other customary termination events. Additionally, the Facility may be terminated by the Company\nat any time without penalty.

In\nconnection with the Facility, also on April 10, 2026, the Company entered the Registration Rights Agreement, pursuant to which the Company\nagreed to file and maintain a registration statement registering the resale of the shares of Common Stock issuable pursuant to the Facility\nwithin thirty (30) calendar days of the date of the Registration Rights Agreement, which thirty (30) day period was subsequently waived.\nThe Company has agreed to use its best efforts to cause the registration statement to be declared effective as soon as practicable, but\nin no event later than ninety (90) calendar days of the date of the Registration Rights Agreement (subject to certain extensions), and\nto keep the registration statement continuously effective from the date on which the Securities and Exchange Commission declares it effective\nuntil (i) the date on which the Selling Stockholder has sold all the Registrable Securities, as defined in the Registration Rights Agreement,\ncovered thereby, (ii) the termination date of the Facility if, as of such termination date, the Selling Stockholder holds no Registrable\nSecurities, and (iii) the date on which the Registrable Securities may be resold by the Selling Stockholder without registration and\nwithout regard to any volume or manner-of-sale limitations by reason of Rule 144 as promulgated by the Securities and Exchange Commission\nunder the Securities Act.

Pursuant\nto the Registration Rights Agreement, we agreed to file one or more additional registration statements for the resale of the Registrable\nSecurities (as defined in the Registration Rights Agreement) if necessary. To continue to issue and sell shares of Common Stock pursuant\nto the Facility, we will be required to file one or more additional registration statements for the resale of additional shares of Common\nStock issuable pursuant to the terms of the Facility, if no additional shares of Common Stock are available for resale pursuant to an\neffective resale registration statement.

The\nCompany has also granted the Selling Stockholder customary indemnification rights in connection with the Registration Rights Agreement,\nand the Selling Stockholder has also granted the Company customary indemnification rights in connection with the Registration Rights\nAgreement.

The\nactual number of shares of our Common Stock issuable by us in connection with the Facility will vary depending on the then-current market\nprice of the shares of our Common Stock sold to the Selling Stockholder under the Facility. Pursuant to the Facility, we have agreed\nto reserve and register from our duly authorized shares of capital stock not less than 100% of the Reservation Estimate, The Company\nmay raise less than the entire $100 million in aggregate gross proceeds under the Facility.

Curvature\nSecurities, LLC (the “Placement Agent”), acted as the placement agent in connection with the transactions contemplated\nby the Facility, for which the Company has agreed to pay a cash fee, payable at each closing, equal to 3.0% of the aggregate gross proceeds\nraised pursuant to the Facility and to reimburse certain expenses of the Placement Agent.

USE\nOF PROCEEDS

This\nprospectus relates to the shares of Common Stock that may be offered and resold from time to time by the Selling Stockholder. See “Plan\nof Distribution” in this Prospectus for additional information. All of the shares of Common Stock offered by the Selling Stockholder\npursuant to this prospectus will be sold by the Selling Shareholder for its respective account. We will not receive any of the proceeds\nfrom these sales.

We\nmay receive up to $100,000,000 in aggregate gross proceeds from sales of shares of our Common Stock we make to the Selling Stockholder\nunder the Facility. We may choose to sell fewer than $100,000,000 in shares of our Common Stock, or, due to the Ownership Limitation,\nwe may not be able to sell all $100,000,000 in shares of our Common Stock under the Facility, in which case we would raise less than\n$100,000,000 in aggregate gross proceeds under the Facility. It is also possible that we do not sell any shares of our Common Stock under\nthe Facility.

The\nproceeds from any sales of Common Stock to the Selling Stockholder under the Facility must be used by the Company as follows: (i) twenty\nfive percent (25%) to acquire cryptocurrencies to serve as a reserve asset, and (ii) the remaining seventy five percent (75%) for working\ncapital purposes and general corporate purposes, provided that no proceeds may be used to repay any advances or loans to any executives\nor employees of the Company or any subsidiary or to make any payments in respect of any related party obligations. We expect to utilize\nthe proceeds primarily for working capital and acquisitions, but we have not determined the amount of net proceeds to be used specifically\nfor any such purposes. The amounts and timing of our actual expenditures may vary significantly and will depend on numerous factors,\nincluding market conditions, cash generated or used by our operations, business developments, industry developments and opportunities\nthat may arise. We may find it necessary or advisable to use portions of the proceeds we receive from our sales of shares of Common Stock\nto the Selling Stockholder under the Facility for other purposes.

DIVIDEND\nPOLICY

We\nhave never paid or declared any cash dividends on our Common Stock, and we do not anticipate paying any cash dividends on our Common\nStock in the foreseeable future. We currently intend to use all available funds and any future earnings for use in financing the growth\nof our business and to meet our series A preferred stock dividend obligations. Any future determination to pay dividends will be at the\ndiscretion of our Board and will depend upon a number of factors, including our results of operations, financial condition, future prospects,\ncontractual restrictions, restrictions imposed by applicable law and other factors our Board deems relevant.

DETERMINATION\nOF OFFERING PRICE

We\ncannot currently determine the price or prices at which shares of our Common Stock may be resold by the Selling Stockholder under this\nprospectus. The actual offering price by the Selling Stockholder of the shares of Common Stock covered by this prospectus will be determined\nby prevailing market prices at the time of the sale, by private transactions negotiated by the Selling Stockholder or as otherwise described\nin the section under the heading “Plan of Distribution.”

SELLING\nSTOCKHOLDER

The\nshares of Common Stock being offered by the Selling Stockholder are those which may be issued to the Selling Stockholder pursuant to\nthe Facility and the Commitment Shares. We are registering these shares of Common Stock in order to permit the Selling Stockholder to\noffer the shares of Common Stock for resale from time to time. Should we direct the Selling Stockholder to purchase shares of Common\nStock pursuant to the Facility, it may resell such shares that it purchased under the Facility pursuant to this prospectus.

Except\nas otherwise set forth in this prospectus, neither the Selling Stockholder nor any of its affiliates have held a position or office,\nor had any other material relationship, with our Company within the past three years.

We\ndo not know when or in what amounts the Selling Stockholder may offer shares of Common Stock for sale. The Selling Stockholder may elect\nnot to sell any or all of the shares of Common Stock offered by this prospectus. Because the Selling Stockholder may offer all, some\nor none of the shares, we cannot estimate the number of the shares that will be held by the Selling Stockholder after completion of this\noffering. However, for purposes of this table, we have assumed that, after completion of the offering, all of the shares covered by this\nprospectus will be sold by the Selling Stockholder.

The following table presents information regarding the Selling Stockholder.\nThe information concerning beneficial ownership has been taken from our stock transfer records and information provided by the Selling\nStockholder and is dated as of October 23, 2026. Beneficial ownership has been calculated in accordance with the rules of the SEC, which\ngenerally attribute beneficial ownership of securities to persons who possess sole or shared voting power or investment power with respect\nto those securities and include shares of Common Stock issuable pursuant to any options, warrants, or rights, or through the conversion\nof securities, that are either immediately convertible or exercisable or convertible or exercisable within 60 days of October 23, 2026.

\n \n \n \n \n \n \n \n \n \n \n \n \n

Selling Stockholder

Shares
\nBeneficially
\nOwned
\nBefore
\nOffering

Percentage of
\nOutstanding
\nShares
\nBeneficially
\nOwned
\nBefore
\nOffering
\n(%)

Number of
\nShares being
\nRegistered/to
\nbe Sold in
\nthe Offering

Percentage of
\nOutstanding
\nShares
\nBeneficially
\nOwned After
\nOffering
\n(%)

SZOP Opportunities I, LLC ⁽¹⁾

277,385

⁽²⁾

9.99

105,223,881

⁽³⁾

SZOP\n Opportunities I LLC (“SZOP”) is wholly-owned by SZOP Opportunities Management\n LLC (“SZOP Management”). Voting and investment decisions with respect\n to these securities are made by a majority of the members of SZOP Management, comprised of\n three persons: Kerry Propper, Isaac Barber, and Jack Liu. None of those persons individually\n has voting or dispositive power over the shares and none of those persons therefore are deemed\n to have beneficial ownership over those securities under the so-called “rule of three”\n pursuant to SEC guidance. The address of SZOP Opportunities I, LLC is 1 Penn Plaza, Suite\n 4810, New York, NY 10119.

Represents the sum of (i) 276,385 shares of Common Stock that SZOP\nwill be deemed to beneficially own upon the effectiveness of the registration statement of which this prospectus forms a part and (ii)\nthe Commitment Shares, which is equal to 9.99% of the 2,499,248 shares of Common Stock outstanding as of October 23, 2026.

3.	Assumes\n all shares of Common Stock being registered hereunder are sold and no new shares pursuant\n to the Facility are registered and eligible for resale.

DESCRIPTION\nOF SECURITIES

Authorized\nand Outstanding Capital Stock

The\nfollowing description of our Company’s capital stock and provisions of our restated certificate of incorporation, as amended (“certificate\nof incorporation”) and our amended and restated bylaws (“bylaws”) are summaries and are qualified by reference\nto our Company’s certificate of incorporation and bylaws and reflect the 1-for-50 reverse stock split which took effect Augst 10,\n2026.

The\ntotal number of shares of all classes of capital stock that our Company is authorized to issue is 305,000,000 shares, consisting of (i)\n300,000,000 shares of Common Stock, and (ii) 5,000,000 shares of preferred stock, par value $0.001 per share (the “preferred\nstock”), of which 1,000,000 shares of preferred stock have been designated by our Board of Directors (“Board”)\nas series A preferred stock (the “series A preferred stock”).

On\nAugust 6, 2026, we held our annual meeting of stockholders at which our stockholders, among other things, approved an amendment to our\ncertificate of incorporation to increase the number of authorized shares of Common Stock from 300,000,000 shares to 600,000,000 shares.\nAs of the date of this prospectus, we have not filed that amendment to our certificate of incorporation with the Delaware Division of\nCorporations.

As of\nOctober 23, 2026, our Company had outstanding 2,499,248 shares of Common Stock and 169,459 shares of series A preferred stock.

Common\nStock

The\nholders of our Company’s Common Stock are entitled to one vote per share. In addition, the holders of our Company’s Common\nStock will be entitled to receive dividends ratably, if any, declared by our Company’s Board out of legally available funds; however,\nthe current policy of the Board is to use all available funds and any future earnings for use in financing the growth of our business\nand to meet our series A preferred stock dividend obligations. Pursuant to the Purchase Agreement (defined below), so long as any Notes\nare outstanding, our Company may not, directly or indirectly, redeem, or declare or pay any cash dividend or distribution on, any securities\nof the Company, other than our series A preferred stock, without the prior express written consent of the Holder. We do not anticipate\npaying any cash dividends on our Common Stock for the foreseeable future. Upon liquidation, dissolution or winding-up, the holders of\nour Company’s Common Stock are entitled to share ratably in all assets that are legally available for distribution. The holders\nof our Company’s Common Stock have no pre-emptive, subscription, redemption or conversion rights. The rights, preferences and privileges\nof holders of our Company’s Common Stock are subject to, and may be adversely affected by, the rights of the holders of the series\nA preferred stock, in addition to any other series of preferred stock which may be designated solely by action of the Board and issued\nin the future.

Publicly\ntraded warrants

The\nfollowing summary of certain terms and provisions of the publicly traded warrants we issued as part of our initial public offering. This\nsummary is not complete and is subject to and qualified in its entirety by the provisions of the warrant agency agreement, which is filed\nas an exhibit to our Company’s Annual Report on Form 10-K for the year ended December 31, 2025. You should carefully review the\nterms and provisions set forth in the warrant agency agreement, including the annexes thereto, and the form of publicly traded warrant.

Outstanding.\nAs of the date of this prospectus, we have outstanding publicly traded warrants to purchase 122,345 shares of Common Stock.

Exercisability.\nThe publicly traded warrants are exercisable at any time after August 30, 2022, and at any time up to the date that is five (5) years\nafter August 30, 2022. The publicly traded warrants are exercisable, at the option of each holder, in whole or in part by delivering\nto us a duly executed exercise notice accompanied by payment in full for the number of shares purchased upon such exercise (except in\nthe case of a cashless exercise as discussed below).

Exercise\nLimitation. A holder does not have the right to exercise any portion of the publicly traded warrant if the holder (together with\nits affiliates) would beneficially own in excess of 4.99% of the number of shares of our Common Stock outstanding immediately after giving\neffect to the exercise, as such percentage ownership is determined in accordance with the terms of the publicly traded warrants. However,\nany holder may increase or decrease such percentage to any other percentage not in excess of 9.99%, provided that any increase in such\npercentage shall not be effective until 61 days following notice from the holder to us.

Exercise\nPrice. The exercise price per share of Common Stock purchasable upon exercise of the publicly traded warrants is $125.00 per share,\nwhich represents the minimum exercise price pursuant to the terms of the warrants. The exercise price was reduced from the original exercise\nprice of $250.00 per share as a result of a Dilutive Issuance (as defined in the warrant) that occurred on October 7, 2025, in accordance\nwith Section 3(b) of the publicly traded warrants. The exercise price remains subject to customary anti-dilution adjustments.

Cashless\nExercise. If, at any time during the term of the publicly traded warrants, the issuance of shares of Common Stock upon exercise of\nthe publicly traded warrants is not covered by an effective registration statement, the holder is permitted to effect a cashless exercise\nof the publicly traded warrants (in whole or in part) by having the holder deliver to us a duly executed exercise notice, canceling a\nportion of the publicly traded warrant in payment of the purchase price payable in respect of the number of shares of Common Stock purchased\nupon such exercise.

Rights\nas a Stockholder. Except as otherwise provided for in the publicly traded warrants or by virtue of such holder’s ownership\nof shares of our Common Stock, the holder of a publicly traded warrant does not have the rights or privileges of a holder of our Common\nStock, including any voting rights, until the holder exercises the warrant.

Warrant\nAgent; Global Certificate. The publicly traded warrants are issued in registered form under the warrant agency agreement between\nthe warrant agent and our Company. The publicly traded warrants shall initially be represented only by one or more global warrants deposited\nwith the warrant agent, as custodian on behalf of The Depository Trust Company (DTC) and registered in the name of Cede & Co., a\nnominee of DTC, or as otherwise directed by DTC. Our transfer agent, VStock Transfer LLC will serve as the warrant agent.

Governing\nLaw. The publicly traded warrants and the warrant agency agreement are governed by Delaware law.

Placement\nAgent Warrants

As additional compensation for EF Hutton’s\nservices as our IPO placement agent, we agreed to issue warrants to EF Hutton or its designees to purchase 1,653 shares of our Common\nStock at $275.00 (the “IPO placement agent’s warrants”). The IPO placement agent’s warrants may be exercised\nin whole or in part, commencing on a date which is six months from August 25, 2022 until August 25, 2027. The IPO placement agent’s\nwarrants provide for one-time demand registration rights and unlimited “piggyback” registration rights for the shares of\nour Common Stock exercisable thereunder as well as customary anti-dilution provisions (for stock dividends and splits and recapitalizations)\nand anti-dilution protection (adjustment in the number and price of such warrants and the shares underlying such warrants) resulting\nfrom corporate events (which would include dividends, reorganizations, mergers, etc.) and future issuance of Common Stock or Common Stock\nequivalents at prices (or with exercise and/or conversion prices) below the offering price as permitted under FINRA Rule 5110(g)(8)(E).\nThe demand registration rights and piggyback registration rights will terminate on the fifth anniversary and seventh anniversary of the\ncommencement of sales of the offering, respectively, in compliance with FINRA Rules 5110(g)(8)(C) and (D).

Private\nPlacement Warrants

In connection\nwith a private placement of units we conducted in October 2025, we issued 14,717 warrants with an exercise price of $125.00. The warrants\nare exercisable in whole or in part, at any time, beginning on October 23, 2025 and expiring on August 30, 2027. The warrants contain\ncustomary anti-dilution provisions (for stock dividends and splits and recapitalizations).

Series\nA Preferred Stock

Our\nseries A preferred stock is senior in rank to shares of Common Stock with respect to dividends, liquidation and dissolution. Each share\nof Series A preferred stock carries an annual 12% cumulative, non-compounding dividend based on the cash amount invested into the Series\nA preferred stock, payable quarterly. Dividends on Series A preferred stock will be paid prior to any dividends on any other class of\nshares, including Common Stock. In the event of any liquidation, dissolution or winding up of our Company, the proceeds shall be paid\nas follows: (i) first, pay the purchase price plus accrued dividends, on each share of Series A preferred stock; and (ii) next, the balance\nof any proceeds shall be distributed pro rata to holders of Common Stock or other junior securities. The Series A preferred stock shall\nbe redeemable at the option of our Company commencing any time after January 1, 2026 at a price equal to the purchase price ($25.00 per\nshare) plus accrued dividends, on each share of Series A preferred stock.

Except\nas otherwise required by law, the Series A preferred stock have no voting rights other than with respect to the following where the Series\nA preferred stock will vote as a separate class: (a) the creation or authorization of any securities of the Company that ranks superior\nto or in parity with the Series A preferred stock in rights, preferences, or privileges, (b) the amending, altering, modifying, or repealing\nthe sections of the certificate of incorporation relating to the Series A preferred stock, (c) redeeming, purchasing, or otherwise acquiring\nor paying or declaring any dividend or other distribution on (or pay into or set aside for a sinking fund for any such purpose) any capital\nstock of the Company; provided, that this restriction shall not apply to (i) the redemption or repurchase of or the payment of\ndividends on Shares of Series A preferred stock, (ii) the declaration or payment of any dividend or distribution payable on the Common\nStock in shares of Common Stock, or (iii) the repurchase of junior securities held by employees or consultants of the Company upon termination\nof their employment or services pursuant to agreements providing for such repurchase; (d) enter into, or become subject to, any agreement\nor instrument or other obligation which by its terms restricts the Company’s ability to perform its obligations relating to the\nsections of the certificate of incorporation relating to the Series A preferred stock, including the ability of the Company to pay dividends\nor make any redemption or other liquidation payment required hereunder; or (e) agree or commit to do any of the foregoing.

On\nor before 180 days following the sale of at least 600,000 shares of the Series A preferred stock, our Company shall register the Series\nA preferred stock by preparing and filing one registration statement, or if necessary more than one registration statement, of our Company\nin compliance with the Securities Act or the Exchange Act and thereafter apply to list the Series A preferred stock on a U.S. stock exchange\nor develop a public trading market for the Series A preferred stock by soliciting securities brokers to become market makers of the series\nA preferred on an established over the counter trading market, such as the OTC Markets. Our series A preferred stock became quoted and\nbegan trading on the OTCQB on October 30, 2024 under the symbol “ONFOP.”

2020\nEquity Incentive Plan

On\nJuly 23, 2020, we adopted the Onfolio Holdings Inc. 2020 Equity Incentive Plan, as amended, (the “2020 Plan”), which\nwas approved by both our Board and our stockholders. Under the 2020 Plan, our Company may grant awards to our employees, consultants\nand directors and such other individuals who are reasonably expected to become employees, consultants and directors. Awards that may\nbe granted under the 2020 Plan include: incentive stock options, non- qualified stock options, stock appreciation rights, restricted\nawards, performance share awards, cash awards, and other equity-based awards. The aggregate number of shares of our Common Stock that\nmay be issued pursuant to stock awards under our 2020 Plan is 52,000 shares, except at any given time, the number of shares that may\nbe issued pursuant to the 2020 Plan cannot exceed the number of shares that is equal to 20% of our Company’s total shares of Common\nStock outstanding at the time of any grant of awards under the 2020 Plan.

As\nof December 31, 2025, the Company has awarded a total of 861,860 options with a weighted average exercise price of $0.93 per share, and\n531,860 shares of Common Stock are issuable upon the exercise of outstanding stock options.

Convertible\nNotes

On\nNovember 17, 2025, the Company and the investor signatory thereto (the “Holder”) entered into (i) that certain Securities\nPurchase Agreement (as amended, restated and modified from time to time, the “Purchase Agreement”), pursuant to which,\namong other things, the Company issued to the Holder (a) a senior secured convertible note in the aggregate principal amount of $6,000,000\n(the “Note”) and (b) a right to receive Common Stock of the Company (the “Right”), and (ii) that\ncertain Registration Rights Agreement (the “November Registration Rights Agreement”, and together with the Purchase\nAgreement, the Note, the Right, and the November Registration Rights Agreement, the “Note Transaction Documents”).

Senior\nSecured Convertible Notes. Pursuant to the Purchase Agreement, the Company issued the Note maturing on November 17, 2027, which is\nconvertible into shares of Common Stock at a conversion price of $0.984. At any time the Holder may, at the Holder’s option, convert\nall, or any part of the Note at the lower of (i) the applicable Conversion Price (as defined in the Note) as in effect on the applicable\nConversion Date (as defined in the Note) and (ii) the greater of (x) the Floor Price (as defined in the Note) and (y) (i) 92% of the\nlowest VWAP (as defined in the Note) of the Common Stock of any Trading Day (as defined in the Note) during the ten (10) consecutive\nTrading Day period ending and including the Trading Day immediately preceding the delivery or deemed delivery of the applicable Conversion\nNotice (as defined in the Note) or (ii) during the occurrence and continuance of an Event of Default (as defined in the Note), 85% of\nthe lowest VWAP of the Common Stock of any Trading Day during the twenty (20) consecutive Trading Day period ending and including the\nTrading Day immediately preceding the delivery or deemed delivery of the applicable Conversion Notice. The initial Floor Price was $0.22\n(as adjusted for share splits, share dividends, share combinations, recapitalizations and similar events) provided that if on the six\nmonth anniversary of the date the Note was issued, the Floor Price shall be adjusted to the lower of (i) the Floor Price then in effect\nand (ii) 20% of the lower of (x) the closing price of the shares of Common Stock on Nasdaq as of the Trading Day ended immediately prior\nto such applicable six month anniversary date and (y) the quotient of (I) the sum of each the closing price of the shares of Common Stock\non Nasdaq on each Trading Day of the five (5) Trading Day period ended on, and including, the Trading Day ended immediately prior to\nsuch applicable six month anniversary date, divided by (II) five.

Subject\nto the terms and conditions of the Purchase Agreement, the Company may require the Holder to participate in one or more additional closings\nfor the purchase by the Holder and the sale by the Company, of (a) additional Notes in the aggregate original principal amount of $2,000,000,\nor such other amount as the Company and the Holder shall mutually agree in writing, and (b) additional Notes with an aggregate original\nprincipal amount not to exceed $292,000,000, or such other amount as the Company and the Holder shall mutually agree in writing.

The\nNotes also contain certain negative covenants, including prohibitions on the incurrence of indebtedness, liens, restrictions on redemption\nand cash dividends, restrictions on the transfer of assets and changes in the nature of business, as well as standard and customary events\nof default including, but not limited to, failure to make payments when due, failure to observe or perform covenants or agreements contained\nin the Notes, existence of a default or event of default under any of the Transaction Documents (as defined in the Purchase Agreement),\nthe bankruptcy or insolvency of the Company or any of its subsidiaries and unsatisfied judgments against the Company.

Right\nto Receive Common Stock. On November 17, 2025 in connection with the Purchase Agreement, the Company issued to the Holder the Rights,\nexercisable for the Right Amount (as defined below) in shares of Common Stock. The Rights shall be exercisable between November 17, 2025,\nand May 17, 2033. “Right Amount” means the underlying value of this Right, which initially shall be zero and shall increase\non each calendar day on or after November 17, 2025, through and including, May 17, 2033, by the Right Daily Incremental Amount (as defined\nin the Rights) and any accrued and unpaid late charges related thereto.

Registration\nRights Agreement. On November 17, 2025, the Company also entered into a registration rights agreement (the “November Registration\nRights Agreement”) with the Holder, which provides, subject to certain limitations, the Holder with certain registration rights\nfor the shares of Common Stock issuable upon conversion of the Notes.

Anti-Takeover\nProvisions

Certain\nof our charter and statutory provisions could make the removal of our management and directors more difficult and may discourage transactions\nthat otherwise could involve payment of a premium over prevailing market prices for our Common Stock. Furthermore, the existence of the\nforegoing provisions, as well as the significant Common Stock beneficially owned by our executive officers, and certain members of our\nBoard, could lower the price that investors might be willing to pay in the future for shares of our Common Stock. They could also deter\npotential acquirers of our Company, thereby reducing the likelihood that you could receive a premium for your Common Stock in an acquisition.

Certificate\nof Incorporation and Bylaws

Provisions\nof our certificate of incorporation and bylaws may delay or discourage transactions involving an actual or potential change in control\nor change in our management, including transactions in which stockholders might otherwise receive a premium for their shares, or transactions\nthat our stockholders might otherwise deem to be in their best interests. Therefore, these provisions could adversely affect the price\nof our Common Stock. Among other things, subject to the rights of holders of any series of preferred stock, our certificate of incorporation\nand bylaws:

\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n

	●	empower\n our Board to fix the number of directors of our Company solely by resolution;

	●	do\n not allow for cumulative voting in the election of directors, which would otherwise allow\n less than a majority of stockholders to elect director candidates;

	●	empower\n our Board to fill any vacancy on our Board, whether such vacancy occurs as a result of an\n increase in the number of directors or otherwise;

	●	provide\n that special meetings of our stockholders may only be called by the Board or the chair of\n the Board (except that stockholders may also call special meetings of our stockholders so\n long as such stockholders beneficially owns at least 25% of the voting power of the outstanding\n shares of our stock);

	●	establish\n advance notice procedures with regard to stockholder proposals relating to the nomination\n of candidates for election as directors or new business to be brought before meetings of\n our stockholders;

	●	provide\n our Board the ability to authorize undesignated preferred stock. This ability makes it possible\n for our Board directors to issue, without stockholder approval, preferred stock with voting\n or other rights or preferences that could impede the success of any attempt to change control\n of us;

	●	provide\n that any director or the entire Board may be removed from office at any time, but only for\n cause and only by the affirmative vote of the holders of at least 66 2/3% in voting power\n of the stock of the Company entitled to vote thereon;

	●	provide\n that our Board is expressly authorized to adopt, amend or repeal our bylaws; and

	●	provide\n that our directors will be elected by a plurality of the votes cast in the election of directors.

Delaware\nLaw

Section\n203 of the Delaware General Corporation Law (“DGCL”) is applicable to takeovers of certain Delaware corporations,\nincluding us. Subject to exceptions enumerated in Section 203, Section 203 provides that a corporation shall not engage in any business\ncombination with any “interested stockholder” for a three-year period following the date that the stockholder becomes an\ninterested stockholder unless:

\n\n\n\n\n\n\n\n\n

	●	prior\n to that date, the board of directors of the corporation approved either the business combination\n or the transaction that resulted in the stockholder becoming an interested stockholder;

	●	upon\n consummation of the transaction that resulted in the stockholder becoming an interested stockholder,\n the interested stockholder owned at least 85% of the voting stock of the corporation outstanding\n at the time the transaction commenced, though some shares may be excluded from the calculation;\n or

	●	on\n or subsequent to that date, the business combination is approved by the board of directors\n of the corporation and by the affirmative votes of holders of at least two- thirds of the\n outstanding voting stock that is not owned by the interested stockholder.

Except\nas specified in Section 203, an interested stockholder is generally defined to include any person who, together with any affiliates or\nassociates of that person, beneficially owns, directly or indirectly, 15% or more of the outstanding voting stock of the corporation,\nor is an affiliate or associate of the corporation and was the owner of 15% or more of the outstanding voting stock of the corporation,\nany time within three years immediately prior to the relevant date. Under certain circumstances, Section 203 makes it more difficult\nfor an interested stockholder to effect various business combinations with a corporation for a three-year period, although the stockholders\nmay elect not to be governed by this section, by adopting an amendment to the certificate of incorporation or bylaws, effective 12 months\nafter adoption. Our certificate of incorporation and bylaws do not opt out from the restrictions imposed under Section 203. We anticipate\nthat the provisions of Section 203 may encourage companies interested in acquiring us to negotiate in advance with the board because\nthe stockholder approval requirement would be avoided if a majority of the directors then in office excluding an interested stockholder\napprove either the business combination or the transaction that resulted in the stockholder becoming an interested stockholder. These\nprovisions may have the effect of deterring hostile takeovers or delaying changes in control, which could depress the market price of\nour Common Stock and deprive stockholders of opportunities to realize a premium on shares of Common Stock held by them.

Contractual\nProvisions

Our\naward agreements related to our 2020 Plan may include change-in-control provisions that allow us to grant options or other awards pursuant\nto our 2020 Plan that may become vested immediately upon a change in control. The terms of change of control provisions contained in\ncertain of our senior executive employee agreements may also discourage a change in control of our Company.

Our\nBoard also has the power to adopt a stockholder rights plan that could delay or prevent a change in control of our Company even if the\nchange in control is generally beneficial to our stockholders. These plans, sometimes called “poison pills”, are oftentimes\ncriticized by institutional investors or their advisors and could affect our rating by such investors or advisors. If our Board adopts\nsuch a plan, it might have the effect of reducing the price that new investors are willing to pay for shares of our Common Stock.

Exclusive\nForum Provision

Our\ncertificate of incorporation and bylaws provide that unless our Company consents in writing to the selection of an alternative forum,\nthe Court of Chancery of the State of Delaware (or, if the Court of Chancery does not have jurisdiction, the federal district court for\nthe District of Delaware) shall, to the fullest extent permitted by law, be the sole and exclusive forum for:

\n\n\n\n\n\n\n\n\n\n\n\n\n

	●	any\n derivative action or proceeding brought on behalf of the Company;

	●	any\n action asserting a claim of breach of a fiduciary duty owed by any director, officer or other\n employee of the Company to the Company or the Company’s stockholders;

	●	any\n action arising pursuant to any provision of the DGCL or our certificate of incorporation\n or bylaws (as either may be amended from time to time); or

	●	any\n action asserting a claim governed by the internal affairs doctrine.

Unless\nour Company consents in writing to the selection of an alternative forum, the federal district courts of the United States of America\nshall be the exclusive forum for the resolution of any complaint asserting a cause of action arising under the Securities Act. Any person\nor entity purchasing or otherwise acquiring or holding any interest in shares of capital stock of our Company shall be deemed to have\nnotice of and consented to the provisions of our certificate of incorporation.

Further,\nif any action the subject matter of which is within the scope of the section immediately above is filed in a court other than a court\nlocated within the State of Delaware (a “Foreign Action”) in the name of any stockholder, such stockholder shall be\ndeemed to have consented to (i) the personal jurisdiction of the state and federal courts located within the State of Delaware in connection\nwith any action brought in any such court to enforce section immediately above (an “FSC Enforcement Action”) and (ii)\nhaving service of process made upon such stockholder in any such FSC Enforcement Action by service upon such stockholder’s counsel\nin the Foreign Action as agent for such stockholder.

The\nenforceability of similar choice of forum provisions in other companies’ bylaws and certificates of incorporation has been challenged\nin legal proceedings, and it is possible that, in connection with any action, a court could find the choice of forum provisions contained\nin our certificate of incorporation and bylaws to be inapplicable or unenforceable in such action.

These\nprovisions would not apply to suits brought to enforce a duty or liability created by the Exchange Act, Securities Act or any other claim\nfor which the federal courts have exclusive or concurrent jurisdiction. Any person or entity purchasing or otherwise acquiring any interest\nin our securities shall be deemed to have notice of and consented to these provisions. Our exclusive forum provision will not relieve\nus of our duties to comply with the federal securities laws and the rules and regulations thereunder, and our stockholders will not be\ndeemed to have waived our compliance with these laws, rules and regulations. Together, these charter, statutory and contractual provisions\ncould make the removal of our management and directors more difficult and may discourage transactions that otherwise could involve payment\nof a premium over prevailing market prices for our Common Stock. Furthermore, the existence of the foregoing provisions, as well as the\nsignificant Common Stock beneficially owned by our founder, executive officers, members of our Board, and others could limit the price\nthat investors might be willing to pay in the future for shares of our Common Stock. They could also deter potential acquirers of our\nCompany, thereby reducing the likelihood that you could receive a premium for your Common Stock in an acquisition.

PLAN\nOF DISTRIBUTION

We\nare registering $55,000,000 of shares of Common Stock to permit the resale or transfer of these shares of Common Stock by the Selling\nStockholder from time to time after the date of this prospectus. We will not receive any of the proceeds from the sale by the Selling\nStockholder of the shares of Common Stock. We will bear all fees and expenses incident to our obligation to register the shares of Common\nStock hereunder.

The\nSelling Stockholder may sell or transfer the securities by one or more of the following methods, without limitation:

\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n

	●	Block\n trades in which the broker or dealer so engaged will attempt to sell the securities as agent\n but may position and resell a portion of the block as principal to facilitate the transaction;\n purchases by a broker or dealer as principal and resale by the broker or dealer for its own\n account pursuant to this prospectus;

	●	an\n exchange distribution in accordance with the rules of any stock exchange on which the securities\n are listed;

	●	ordinary\n brokerage transactions and transactions in which the broker solicits purchases;

	●	privately\n negotiated transactions;

	●	through\n the distribution of the securities by the Selling Stockholders to their partners, members\n or equity holders;

	●	one\n or more underwritten offerings on a firm commitment or best efforts basis;

	●	any\n combination of any of these methods of sale; and

	●	any\n other method permitted pursuant to applicable law.

The\nSelling Stockholder may elect to make a pro rata in-kind distribution of securities to its members, partners or equity holders pursuant\nto the registration statement of which this prospectus forms a part by delivering a prospectus with a plan of distribution. Such members,\npartners or equity holders would thereby receive freely tradeable securities pursuant to the distribution through a registration statement.

The\nSelling Stockholder may also transfer the securities by gift. We do not know of any arrangements by the Selling Stockholder for the sale\nof any of the securities. The Selling Stockholder may engage brokers and dealers, and any brokers or dealers may arrange for other brokers\nor dealers to participate in effecting sales of the securities. These brokers, dealers or underwriters may act as principals, or as an\nagent of the Selling Stockholder. Broker-dealers may agree with the Selling Stockholder to sell a specified number of the securities\nat a stipulated price per security. If the broker-dealer is unable to sell securities acting as agent for the Selling Stockholder, it\nmay purchase as principal any unsold securities at the stipulated price. Broker-dealers who acquire securities as principals may thereafter\nresell the securities from time to time in transactions in any stock exchange or automated interdealer quotation system on which the\nsecurities are then listed, at prices and on terms then prevailing at the time of sale, at prices related to the then-current market\nprice or in negotiated transactions. Broker-dealers may use block transactions and sales to and through broker-dealers, including transactions\nof the nature described above.

The\nSelling Stockholder may also sell the shares of Common Stock in accordance with Rule 144 under the Securities Act, when such resale under\nRule 144 becomes available, rather than pursuant to this prospectus, regardless of whether the securities are covered by this prospectus.

From\ntime to time, the Selling Stockholder may pledge, hypothecate or grant a security interest in some or all of the securities owned by\nit. The pledgees, secured parties or persons to whom the securities have been hypothecated will, upon foreclosure in the event of default,\nbe deemed to be Selling Stockholders. The respective number of each of the Selling Stockholders’ securities offered under this\nprospectus will decrease as and when they takes such actions. The plan of distribution for the Selling Stockholders’ securities\nwill otherwise remain unchanged.

To\nthe extent required under the Securities Act, the aggregate amount of Selling Stockholder’s securities being offered and the terms\nof the offering, the names of any agents, brokers, dealers or underwriters and any applicable commission with respect to a particular\noffer will be set forth in an accompanying prospectus supplement. Any underwriters, dealers, brokers or agents participating in the distribution\nof the securities may receive compensation in the form of underwriting discounts, concessions, commissions or fees from the Selling Stockholders\nand/or purchasers of Selling Stockholders Common Stock, for whom they may act (which compensation as to a particular broker-dealer might\nbe in excess of customary commissions).

In\nconnection with the sale of the securities or interests therein, the Selling Stockholder may enter into hedging transactions with broker-dealers\nor other financial institutions, which may in turn engage in short sales of the securities in the course of hedging the positions they\nassume. The Selling Stockholder may also enter into option or other transactions with broker-dealers or other financial institutions\nor create one or more derivative securities which require the delivery to such broker-dealer or other financial institution of securities\noffered by this prospectus, which securities such broker-dealer or other financial institution may resell pursuant to this prospectus\n(as supplemented or amended to reflect such transaction).

The\nSelling Stockholder may be deemed an “underwriter” and any underwriters, brokers, dealers or agents that participate in the\ndistribution of the securities may be deemed to be “underwriters” within the meaning of Section 2(a)(11) of the Securities\nAct, and any discounts, concessions, commissions or fees received by them and any profit on the resale of the securities sold by them\nmay be deemed to be underwriting discounts and commissions.

We\nalso have agreed to indemnify the Selling Stockholder and certain other persons against certain liabilities in connection with the offering\nof our Common Stock offered hereby, including liabilities arising under the Securities Act or, if such indemnity is unavailable, to contribute\namounts required to be paid in respect of such liabilities. The Selling Stockholder has agreed to indemnify us against liabilities under\nthe Securities Act that may arise from certain written information furnished to us by the Selling Stockholders specifically for use in\nthis prospectus or, if such indemnity is unavailable, to contribute amounts required to be paid in respect of such liabilities. Insofar\nas indemnification for liabilities arising under the Securities Act may be permitted to our directors, officers, and controlling persons,\nwe have been advised that in the opinion of the SEC this indemnification is against public policy as expressed in the Securities Act\nand is therefore, unenforceable.

We\nhave agreed to keep this prospectus effective until (i) the date on which the Selling Stockholder shall have resold all the Registrable\nSecurities (as such term is defined in the Registration Rights Agreement) covered thereby, (ii) the date of termination of the Facility\nif, as of such termination date, the Selling Stockholder holds no Registrable Securities, and (iii) the date on which the Registrable\nSecurities may be resold by the Selling Stockholder without any restriction pursuant to Rule 144 as determined by the counsel to the\nCompany pursuant to a written opinion letter to such effect, addressed and acceptable to the Company’s transfer agent.

To\nthe extent required, this prospectus may be amended and/or supplemented from time to time to describe a specific plan of distribution.

The\nSelling Stockholder may also sell shares of Common Stock under Rule 144 promulgated under the Securities Act, if available, rather than\nunder this prospectus. In addition, the Selling Stockholder may transfer the shares of Common Stock by other means not described in this\nprospectus. If the Selling Stockholder effect such transactions by selling the shares of Common Stock to or through underwriters, broker-dealers\nor agents, such underwriters, broker-dealers or agents may receive commissions in the form of discounts, concessions or commissions from\nthe Selling Stockholder or commissions from purchasers of the shares of Common Stock for whom they may act as agent or to whom they may\nsell as principal (which discounts, concessions or commissions as to particular underwriters, broker-dealers or agents may be in excess\nof those customary in the types of transactions involved). In connection with sales of shares of Common Stock or otherwise, the Selling\nStockholder may enter into hedging transactions with broker-dealers, which may in turn engage in short sales of the shares of Common\nStock in the course of hedging in positions they assume. The Selling Stockholder may also sell shares of Common Stock short and deliver\nthe shares covered by this prospectus to close out short positions and to return borrowed shares in connection with such short sales.\nThe Selling Stockholder may also loan or pledge the shares to broker-dealers that in turn may sell such shares.

The\nSelling Stockholder may pledge or grant a security interest in some or all of the Notes, the Rights, or shares of Common Stock owned\nby them and, if they default in the performance of their secured obligations, the pledgees or secured parties may offer and sell the\nshares from time to time pursuant to this prospectus or any amendment to this prospectus under Rule 424(b)(3) or other applicable provision\nof the Securities Act amending, if necessary, the list of Selling Stockholders to include the pledgee, transferee or other successors\nin interest as Selling Stockholder under this prospectus. The Selling Stockholder also may transfer and donate the shares in other circumstances\nin which case the transferees, donees, pledgees or other successors in interest will be the selling beneficial owners for purposes of\nthis prospectus.

To\nthe extent required by the Securities Act and the rules and regulations thereunder, the Selling Stockholder and any broker-dealer participating\nin the distribution of the shares of Common Stock may be deemed to be “underwriters” within the meaning of the Securities\nAct, and any commission paid, or any discounts or concessions allowed to, any such broker-dealer may be deemed to be underwriting commissions\nor discounts under the Securities Act. At the time a particular offering of the shares is made, a prospectus supplement, if required,\nwill be distributed, which will set forth the aggregate amount of shares of Common Stock being offered and the terms of the offering,\nincluding the name or names of any broker-dealers or agents, any discounts, commissions and other terms constituting compensation from\nthe Selling Stockholder and any discounts, commissions or concessions allowed or re-allowed or paid to broker-dealers.

Under\nthe securities laws of some states, the shares may be sold in such states only through registered or licensed brokers or dealers. In\naddition, in some states the shares of Common Stock may not be sold unless such shares have been registered or qualified for sale in\nsuch state or an exemption from registration or qualification is available and is complied with.

There\ncan be no assurance that any Selling Stockholder will sell any or all of the shares registered pursuant to the registration statement,\nof which this prospectus forms a part.

The\nSelling Stockholder and any other person participating in such distribution will be subject to applicable provisions of the Securities\nExchange Act of 1934, as amended, and the rules and regulations thereunder, including, without limitation, to the extent applicable,\nRegulation M of the Exchange Act, which may limit the timing of purchases and sales of any of the shares of Common Stock by the Selling\nStockholder and any other participating person. To the extent applicable, Regulation M may also restrict the ability of any person engaged\nin the distribution of the shares of Common Stock to engage in market-making activities with respect to the shares of Common Stock. All\nof the foregoing may affect the marketability of the shares of Common Stock and the ability of any person or entity to engage in market-making\nactivities with respect to the shares of Common Stock.

We will pay all expenses of the registration of the shares of Common\nStock pursuant to the Registration Rights Agreement, estimated to be approximately $49,785.05 in total, including, without limitation,\nSecurities and Exchange Commission filing fees and expenses of compliance with state securities or “blue sky” laws; provided,\nhowever, a Selling Stockholder will pay all underwriting discounts and selling commissions, if any. We will indemnify the Selling Stockholder\nagainst liabilities, including some liabilities under the Securities Act in accordance with the Registration Rights Agreement or the Selling\nStockholder will be entitled to contribution. We may be indemnified by the Selling Stockholder against civil liabilities, including liabilities\nunder the Securities Act that may arise from any written information furnished to us by the Selling Stockholder specifically for use in\nthis prospectus, in accordance with the Registration Rights Agreement or we may be entitled to contribution.

Once\nsold under the registration statement, of which this prospectus forms a part, the shares of Common Stock will be freely tradable in the\nhands of persons other than our affiliates.

LEGAL\nMATTERS

The\nvalidity of the shares of Common Stock offered by this prospectus will be passed upon for us by David M. Bovi, P.A.

EXPERTS

The\nfinancial statements of Onfolio Holdings Inc. as of December 31, 2025 and 2024 have been included in this prospectus and have been so\nincluded in reliance on the report of Astra Audit & Advisory LLC, an independent registered public accounting firm, (such report\nincluding an explanatory paragraph regarding our ability to continue as a going concern), given on the authority of said firm as experts\nin auditing and accounting.

INCORPORATION\nOF CERTAIN DOCUMENTS BYREFERENCE

The\nSEC allows us to “incorporate by reference” information that we file with it into this prospectus, which means that we can\ndisclose important information to you by referring you to those documents. The information incorporated by reference is an important\npart of this prospectus. The information incorporated by reference is considered to be a part of this prospectus, and information that\nwe file later with the SEC will automatically update and supersede information contained in this prospectus.

We\nincorporate by reference the following documents or information that we have filed with the SEC:

\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n

	●	Our\n Annual Report on Form\n 10-K for the year ended December 31, 2025, filed with the SEC on March 31, 2026.

	●	Our\n Quarterly Report on Form\n 10-Q for the quarterly period ended March 31, 2026, filed with the SEC on May 15, 2026.

	●	Our\n Quarterly Report on Form\n 10-Q for the quarterly period ended June 30, 2026, filed with the SEC on August 19, 2026.

	●	Our\n Current Reports on Form 8-K filed with the SEC on January\n 9, 2026, January\n 13, 2026, April\n 10, 2026, April\n 16, 2026, May\n 1, 2026, May\n 1, 2026, May\n 14, 2026, May\n 29, 2026, July\n 8, 2026, July\n 9, 2026, July\n 27, 2026, July\n 28, 2026, August\n 10, 2026, August\n 11, 2026, August\n 27, 2026, October\n 5, 2026, October\n 7, 2026, and October\n 20, 2026.

	●	Our\n Definitive Proxy Statement on Schedule 14A filed with the SEC on June\n 18, 2026.

	●	The\n description of the Common Stock contained in the registrant’s registration statement\n on Form\n 8-A filed with the SEC on August 3, 2022, including any amendment or report filed for\n the purpose of updating such description.

All\nother reports and documents filed by us pursuant to Sections 13(a), 13(c), 14 or 15(d) of the Exchange Act after the date that this registration\nstatement becomes effective and after the date of this prospectus but before the termination of the offering of the securities described\nin this prospectus shall be deemed to be incorporated by reference into this prospectus.

Notwithstanding\nthe statements in the preceding paragraphs, no document, report or exhibit (or portion of any of the foregoing) or any other information\nthat we have “furnished” to the SEC pursuant to the Exchange Act shall be incorporated by reference into this prospectus.

Any\nstatement contained in this prospectus or contained in a document incorporated or deemed to be incorporated by reference into this prospectus\nwill be deemed to be modified or superseded to the extent that a statement contained in this prospectus or any subsequently filed supplement\nto this prospectus, or document deemed to be incorporated by reference into this prospectus, modifies or supersedes such statement. Any\nstatements so modified or superseded shall not be deemed, except as so modified or superseded, to constitute a part of this prospectus.

You\nmay request a copy of these filings at no cost, by writing or telephoning us at the following address:

Onfolio\nHoldings Inc.

1007\nNorth Orange Street, 4th Floor

Wilmington, Delaware

Attn:\nDominic Wells

Dom@onfolio.com

(682) 990-6920

WHERE\nYOU CAN FIND MORE INFORMATION

This\nprospectus is part of a registration statement we filed with the SEC. This prospectus does not contain all of the information set forth\nin the registration statement and the exhibits to the registration statement.

For\nfurther information with respect to us and the securities we are offering under this prospectus, we refer you to the registration statement\nand the exhibits and schedules filed as a part of the registration statement. You should rely only on the information contained in this\nprospectus or incorporated by reference into this prospectus. We have not authorized anyone else to provide you with different information.\nWe are not making an offer of these securities in any jurisdiction where the offer is not permitted. You should assume that the information\ncontained in this prospectus, or any document incorporated by reference in this prospectus, is accurate only as of the date of those\nrespective documents, regardless of the time of delivery of this prospectus or any sale of our securities.

We\nfile annual, quarterly and current reports, proxy statements and other information with the SEC. Our SEC filings are available to the\npublic from commercial document retrieval services and over the Internet at the SEC’s website at http://www.sec.gov.

We\nalso maintain a website at www.onfolio.com. You may access our annual reports on Form 10-K, quarterly\nreports on Form 10-Q, current reports on Form 8-K and amendments to those reports filed or furnished pursuant to Section 13(a) or 15(d)\nof the Exchange Act with the SEC free of charge as soon as reasonably practicable after they are electronically filed with, or furnished\nto, the SEC. Information contained on our website is not a part of this prospectus and the inclusion of our website address in this prospectus\nis an inactive textual reference only.

$\"\"$

ONFOLIO\nHOLDINGS INC.

105,223,881\nshares of Common Stock

PRELIMINARY\nPROSPECTUS

PART\nII

INFORMATION\nNOT REQUIRED IN PROSPECTUS

ITEM 13. OTHER EXPENSES OF ISSUANCEAND DISTRIBUTION.

The\nfollowing table sets forth the approximate expenses in connection with this registration statement. All of such expenses are estimates,\nother than the filing fees payable to the Securities and Exchange Commission (“SEC”). We will pay all these expenses.

\n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n

	Amount to be paid
SEC registration fee	$	4,785.05
Accounting fees and expenses	$	10,000.00
Legal fees and expenses	$	25,000.00
Transfer Agent fees and expenses	$	5,000.00
Miscellaneous fees and expenses	$	5,000.00
Total	$	49,785.05

ITEM\n 14. INDEMNIFICATION OF DIRECTORS AND OFFICERS.

Section\n145 of the DGCL, or Section 145, provides that a Delaware corporation may indemnify any person who was, is or is threatened to be made,\nparty to any threatened, pending or completed action, suit or proceeding, whether civil, criminal, administrative or investigative (other\nthan an action by or in the right of such corporation), by reason of the fact that such person is or was an officer, director, employee\nor agent of such corporation or is or was serving at the request of such corporation as a director, officer, employee or agent of another\ncorporation or enterprise. The indemnity may include expenses (including attorneys’ fees), judgments, fines and amounts paid in\nsettlement actually and reasonably incurred by such person in connection with such action, suit or proceeding, provided such person acted\nin good faith and in a manner he reasonably believed to be in or not opposed to the corporation’s best interests and, with respect\nto any criminal action or proceeding, had no reasonable cause to believe that his or her conduct was illegal. A Delaware corporation\nmay indemnify any persons who are, were or are a party to any threatened, pending or completed action or suit by or in the right of the\ncorporation by reason of the fact that such person is or was a director, officer, employee or agent of another corporation or enterprise.\nThe indemnity may include expenses (including attorneys’ fees) actually and reasonably incurred by such person in connection with\nthe defense or settlement of such action or suit, provided such person acted in good faith and in a manner he reasonably believed to\nbe in or not opposed to the corporation’s best interests, provided that no indemnification is permitted without judicial approval\nif the officer, director, employee or agent is adjudged to be liable to the corporation. Where an officer or director is successful on\nthe merits or otherwise in the defense of any action referred to above, the corporation must indemnify him against the expenses which\nsuch officer or director has actually and reasonably incurred.

Section\n145 further authorizes a corporation to purchase and maintain insurance on behalf of any person who is or was a director, officer, employee\nor agent of the corporation or is or was serving at the request of the corporation as a director, officer, employee or agent of another\ncorporation or enterprise, against any liability asserted against him and incurred by him in any such capacity, or arising out of his\nor her status as such, whether or not the corporation would otherwise have the power to indemnify him under Section 145.

II-1

Our\ncertificate of incorporation and bylaws provide that we must indemnify our directors and officers to the fullest extent permitted by\nthe DGCL and must indemnify against all expenses, liability, and loss incurred in investigating, defending or participating in such proceedings.

We\nhave also entered into separate indemnification agreements with our directors and officers. Each indemnification agreement provides,\namong other things, for indemnification to the fullest extent permitted by law and our bylaws against any and all expenses, judgments,\nfines, penalties and amounts paid in settlement of any claim. The indemnification agreements provide for the advancement or payment of\nall expenses to the indemnitee.

The\nindemnification rights set forth above shall not be exclusive of any other right which an indemnified person may have or hereafter acquire\nunder any statute, provision of our certificate of incorporation, our bylaws, agreement, vote of stockholders or disinterested directors\nor otherwise; provided, however, in the case of any such amendment or interpretation, only to the extent that such amendment or interpretation\npermits us to provide broader indemnification rights than we were permitted prior thereto.

ITEM\n15. RECENT SALES OF UNREGISTERED SECURITIES.

During\nthe past three years, our Company has sold the following securities without registering the securities under the under the Securities\nAct of 1933, as amended (the “Securities Act”):

\n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n

Date		Security
Dec.\n 2023		Preferred\n Shares - 22,600 shares with a purchase price of $25 per share issued for cash.
Jan.\n 2024		Preferred\n Shares -17,000 shares with a purchase price of $25 per share issued in connection with a business acquisition.
Jan.\n - Mar. 2024		Preferred\n Shares - 400 shares with a purchase price of $25 per share issued for cash.
June\n 2024		Preferred\n Shares - 800 shares with a purchase price of $25 per share issued for cash.
Oct.\n 2024		Preferred\n Shares -16,400 shares with a purchase price of $25 per share issued in connection with a business acquisition.
Feb.\n 2025		Preferred\n Shares -2,800 shares with a purchase price of $25 per share issued in connection with a business acquisition earnout payment.
Jan.\n - Mar. 2025		Preferred\n Shares - 32,200 shares with a purchase price of $25 per share issued for cash.
Oct.\n 2025		Units\n – 14,717 units (one share of Common Stock and one warrant at $125.00 per share) issued for cash (for aggregate proceeds of approximately\n $1,000,000 gross proceeds).
November\n 2025		Senior\n Secured Convertible Notes – $6,000,000 convertible into shares of Common Stock at $0.984 per share
November\n 2025		Rights\n to Receive Common Stock
April\n 2026		Common\n Shares – 1,000 shares issued as Commitment Shares pursuant to the Facility.

All\nof the securities were offered and sold in reliance upon exemptions from registration under Section 4(a)(2) of the Securities Act and/or\n(i) Rule 506 of Regulation D promulgated thereunder; or (ii) Regulation S promulgated thereunder. Other than as described herein, no\nunderwriters were utilized, and no commissions or fees were paid with respect to any of the above transactions. The Company paid its\nplacement agent a cash fee equal to 8.0% of the face value of the Senior Secured Convertible Notes issued in November 2025.

II-2

ITEM 16. EXHIBITS AND FINANCIAL STATEMENT SCHEDULES.

EXHIBIT INDEX

\n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n

\n Exhibit No.	Description of Exhibit	Location
3.1	Amended and Restated Certificate of Incorporation	Incorporated by reference to Company’s Form S-1 Registration Statement filed with the SEC on 04/07/22
3.2	Certificate of Amendment of Certificate of Incorporation - 2022	Incorporated by reference to Company’s Form S-1 Registration Statement filed with the SEC on 08/16/22
3.3	Certificate of Amendment of Certificate of Incorporation – May 2026	Incorporated by reference to Company’s Form 8-K filed with the SEC on 05/14/26
3.4	Certificate of Amendment of Certificate of Incorporation – 2026 – August 2026	Incorporated by reference to Company’s Form 8-K filed with the SEC on 08/10/26
3.5	Amended and Restated By-Laws - September 2026	Incorporated by reference to Company’s Form 8-K filed with the SEC on 10/05/26
4.1	Warrant Agency Agreement, dated August 30, 2022, between the Company and VStock Transfer LLC	Incorporated by reference to Company’s Form 8-K filed with the SEC on 8/30/22
4.2	Form of Warrant Agreement (included in Exhibit 4.1)	Incorporated by reference to Company’s Form 8-K filed with the SEC on 8/30/2022
4.3	Form of Representative’s Warrant	Incorporated by reference to Company’s Form 8-K filed with the SEC on 7/25/22
4.4	Form of Stock Certificate	Incorporated by reference to Company’s Form S-1 Registration Statement filed with the SEC on 5/13/22
5.1	Opinion of David M. Bovi, P.A.	Filed herewith
10.1+	2020 Equity Incentive Plan	Incorporated by reference to Company’s Form S-1 Registration Statement filed with the SEC on 9/20/22
10.2+	2020 Equity Incentive Plan Amendment No 1	Incorporated by reference to Company’s Form S-1 Registration Statement filed with the SEC on 8/1622
10.3+	Form of Non-Qualified Stock Option Agreement - Employees	Incorporated by reference to Company’s Form S-1 Registration Statement filed with the SEC on 04/07/22
10.4+	Form of Stock Option Exercise Agreement - Employees	Incorporated by reference to Company’s Form S-1 Registration Statement filed with the SEC on 04/07/22
10.5+	Form of Non-Qualified Stock Option Award Agreement - Consultants	Incorporated by reference to Company’s Form S-1 Registration Statement filed with the SEC on 04/07/22
10.6+	Form of Stock Option Exercise Agreement - Consultants	Incorporated by reference to Company’s Form S-1 Registration Statement filed with the SEC on 04/07/22
10.7+	Form of Non-Qualified Stock Option Award Agreement - Non- Employee Directors	Incorporated by reference to Company’s Form S-1 Registration Statement filed with the SEC on 04/07/22
10.8+	Form of Stock Option Exercise Agreement - Non Employee Directors	Incorporated by reference to Company’s Form S-1 Registration Statement filed with the SEC on 04/07/22
10.9+	Form of Restricted Stock Award Agreement - Directors	Incorporated by reference to Company’s Form S-1 Registration Statement filed with the SEC on 04/07/22
10.10+	Non-Employee Director Compensation Policy 2024	Incorporated by reference to Company’s Form 10-K filed with the SEC on 4/16/25
10.12+	Employment Agreement dated as of January 1, 2022, by the Company and Dominic Wells	Incorporated by reference to Company’s Form S-1 Registration Statement filed with the SEC on 04/07/22
10.13+	Employee Agreement Amendment dated as of March 25, 2025, by the Company and Dominic Wells	Incorporated by reference to Company’s Form 10-Q filed with the SEC on 08/14/25
10.14+	Employee Agreement dated as of December 19, 2024, by the Company and Adam Trainor	Incorporated by reference to Company’s Form 8-K filed with the SEC on 12/20/2024

II-3

10.15	Form of Director and Officer Indemnification Agreement	Incorporated by reference to Company’s Form S-1 Registration Statement filed with the SEC on 04/07/22
10.16	Promissory Note - RevenueZen	Incorporated by reference to Company’s Form 8-K filed on 01/04/24
10.17	Form of $400,000 Promissory Note - Eastern Standard	Incorporated by reference to Company’s Form 8-K filed on 10/22/2024
10.18	Form of $850,000 Promissory Note - Eastern Standard	Incorporated by reference to Company’s Form 8-K filed on 10/22/2024
10.19	Form of Security Agreement - Eastern Standard	Incorporated by reference to Company’s Form 8-K filed on 10/22/2024
10.20	Form of Corporate Guarantee	Incorporated by reference to Company’s Form 8-K filed on 10/22/2024
10.21	Securities Purchase Agreement between the Company and Buyers, dated November 17, 2025	Incorporated by reference to Company’s Form 8-K filed with the SEC on 11/19/25
10.22	Form of Senior Secured Convertible Note dated November 17, 2025	Incorporated by reference to Company’s Form 8-K filed with the SEC on 11/19/25
10.23	Form of Right to Receive Common Stock dated November 17, 2025	Incorporated by reference to Company’s Form 8-K filed with the SEC on 11/19/25
10.24	Form of Security and Pledge Agreement dated November 17, 2025	Incorporated by reference to Company’s Form 8-K filed with the SEC on 11/19/25
10.25	Form of Guaranty dated November 17, 2025	Incorporated by reference to Company’s Form 8-K filed with the SEC on 11/19/25
10.26	Form of Registration Rights Agreement dated November 17, 2025	Incorporated by reference to Company’s Form 8-K filed with the SEC on 11/19/25
10.27	Form of Equity Purchase Facility Agreement, dated as of April 10, 2026,	Incorporated by reference to Company’s Form 8-K filed with the SEC on 04/16/26
10.28	Form of Registration Rights Agreement, dated as of April 10, 2026	Incorporated by reference to Company’s Form 8-K filed with the SEC on 04/16/26
10.29	Form of Waiver and Amendment Agreement, dated as of April 10, 2026	Incorporated by reference to Company’s Form 8-K filed with the SEC on 04/16/26
10.30	Eastern Standard Limited Forbearance Agreement and Reaffirmation of Loan Documents	Incorporated by reference to Company’s Form 8-K filed with the SEC on 10/20/26
21.1	Subsidiaries of the Registrant	Incorporated by reference to Company’s Form 10-K filed with the SEC on 03/31/26
23.1	Consent of Independent Registered Public Accounting Firm - Astra Audit & Advisory, LLC	Filed herewith
23.2	Consent of David M. Bovi, P.A. (included in Exhibit 5.1)	Filed herewith
24.1	Power of Attorney (included in the signature page to this Registration Statement)	Filed herewith
107	Filing Fee Table	Filed herewith

\n\n \n \n

+	Indicates a management contract or any compensatory plan, contract\nor arrangement.

II-4

ITEM\n17. UNDERTAKINGS.

The\nundersigned registrant hereby undertakes:

(1)

To\n file, during any period in which offers or sales are being made, a post-effective amendment\n to this registration statement:

(i)

To\n include any prospectus required by section 10(a)(3) of the Securities Act;

(ii)

To\n reflect in the prospectus any facts or events arising after the effective date of the registration\n statement (or the most recent post-effective amendment thereof) which, individually or in\n the aggregate, represent a fundamental change in the information set forth in the registration\n statement. Notwithstanding the foregoing, any increase or decrease in volume of securities\n offered (if the total dollar value of securities offered would not exceed that which was\n registered) and any deviation from the low or high end of the estimated maximum offering\n range may be reflected in the form of prospectus filed with the SEC pursuant to Rule 424(b)\n if, in the aggregate, the changes in volume and price represent no more than 20% change in\n the maximum aggregate offering price set forth in the “Calculation of Registration\n Fee” table in the effective registration statement.

(iii)

To\n include any material information with respect to the plan of distribution not previously\n disclosed in the registration statement or any material change to such information in the\n registration statement;

provided,\nhowever, that paragraphs (i), (ii) and (iii) do not apply if the registration statement is on Form S-1 and the information required\nto be included in a post-effective amendment by those paragraphs is contained in reports filed with or furnished to the Securities and\nExchange Commission by the registrant pursuant to Section 13 or Section 15(d) of the Securities Exchange Act of 1934 that are incorporated\nby reference in the registration statement, or is contained in a form of prospectus filed pursuant to Rule 424(b) that is part of the\nregistration statement;

(2)

That,\n for the purpose of determining any liability under the Securities Act, each such post-effective\n amendment shall be deemed to be a new registration statement relating to the securities offered\n therein, and the offering of such securities at that time shall be deemed to be the initial\n bona fide offering thereof.

(3)

To\n remove from registration by means of a post-effective amendment any of the securities being\n registered which remain unsold at the termination of the offering.

(4)

That,\n for the purpose of determining liability under the Securities Act to any purchaser, if the\n registrant is subject to Rule 430C, each prospectus filed pursuant to Rule 424(b) as part\n of a registration statement relating to an offering, other than registration statements relying\n on Rule 430B or other than prospectuses filed in reliance on Rule 430A, shall be deemed to\n be part of and included in the registration statement as of the date it is first used after\n effectiveness. Provided, however, that no statement made in a registration statement or prospectus\n that is part of the registration statement or made in a document incorporated or deemed incorporated\n by reference into the registration statement or prospectus that is part of the registration\n statement will, as to a purchaser with a time of contract of sale prior to such first use,\n supersede or modify any statement that was made in the registration statement or prospectus\n that was part of the registration statement or made in any such document immediately prior\n to such date of first use.

II-5

(5)

That,\n for the purpose of determining liability of the registrant under the Securities Act to any\n purchaser in the initial distribution of the securities, the undersigned registrant undertakes\n that in a primary offering of securities of the undersigned registrant pursuant to this registration\n statement, regardless of the underwriting method used to sell the securities to the purchaser,\n if the securities are offered or sold to such purchaser by means of any of the following\n communications, the undersigned registrant will be a seller to the purchaser and will be\n considered to offer or sell such securities to such purchaser:

(i)

Any\n preliminary prospectus or prospectus of the undersigned registrant relating to the offering\n required to be filed pursuant to Rule 424;

(ii)

Any\n free writing prospectus relating to the offering prepared by or on behalf of the undersigned\n registrant or used or referred to by the undersigned registrant;

(iii)

The\n portion of any other free writing prospectus relating to the offering containing material\n information about the undersigned registrant or its securities provided by or on behalf of\n the undersigned registrant; and

(iv)

Any\n other communication that is an offer in the offering made by the undersigned registrant to\n the purchaser.

(6)

That,\n for purposes of determining any liability under the Securities Act of 1933, each filing of\n the registrant’s annual report pursuant to section 13(a) or section 15(d) of the Securities\n Exchange Act of 1934 (and, where applicable, each filing of an employee benefit plan’s annual\n report pursuant to section 15(d) of the Securities Exchange Act of 1934) that is incorporated\n by reference in the registration statement shall be deemed to be a new registration statement\n relating to the securities offered therein, and the offering of such securities at that time\n shall be deemed to be the initial bona fide offering thereof.

Insofar\nas indemnification for liabilities arising under the Securities Act may be permitted to directors, officers and controlling persons of\nthe registrant pursuant to the foregoing provisions, or otherwise, the registrant has been advised that in the opinion of the Securities\nand Exchange Commission such indemnification is against public policy as expressed in the Act and is, therefore, unenforceable. In the\nevent that a claim for indemnification against such liabilities (other than the payment by the registrant of expenses incurred or paid\nby a director, officer or controlling person of the registrant in the successful defense of any action, suit or proceeding) is asserted\nby such director, officer or controlling person in connection with the securities being registered, the registrant will, unless in the\nopinion of its counsel the matter has been settled by controlling precedent, submit to a court of appropriate jurisdiction the question\nwhether such indemnification by it is against public policy as expressed in the Securities Act and will be governed by the final adjudication\nof such issue.

II-6

SIGNATURES

Pursuant\nto the requirements of the Securities Act of 1933, the registrant has duly caused this Registration Statement to be signed on its behalf\nby the undersigned, thereunto duly authorized in the City of Wilmington, State of Delaware, on October 23, 2026.

\n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n

ONFOLIO\n HOLDINGS INC.

By:	/s/\n Dominic Wells
Name:	Dominic\n Wells
Title:	Chief\n Executive Officer

POWER\nOF ATTORNEY

KNOW\nALL PERSONS BY THESE PRESENTS, that each person whose signature appears below constitutes and appoints Dominic Wells his or her true\nand lawful attorney-in-fact and agent, with full power of substitution and resubstitution, for him or her and in his or her name, place\nand stead, in any and all capacities, to sign any or all amendments (including post-effective amendments) to this registration statement,\nand to file the same, with all exhibits thereto and other documents in connection therewith, with the Securities and Exchange Commission,\ngranting unto said attorneys-in-fact and agents, full power and authority to do and perform each and every act and thing requisite and\nnecessary to be done in and about the premises, as fully to all intents and purposes as he or she might or could do in person, hereby\nratifying and confirming all that said attorneys-in-fact and agents, or any of them, or their substitutes, may lawfully do or cause to\nbe done by virtue hereof.

Pursuant\nto the requirements of the Securities Act of 1933, this Registration Statement has been signed by the following persons in the capacities\nand on the dates indicated.

Signature	Title	Date

/s/ Dominic Wells	Chief Executive Officer, and Chair of the Board,	October 23, 2026
Dominic Wells	Principal\n Executive Officer

/s/ Adam Trainor	Chief Financial Officer, Chief Operations Officer,	October 23, 2026
Adam Trainor	Principal\n Financial and Accounting Officer

/s/ Andrew Lawrence	Director	October 23, 2026
Andrew Lawrence

/s/ David McKeegan	Director	October 23, 2026
David McKeegan

/s/ Mark N. Schwartz	Director	October 23, 2026
Mark N. Schwartz

II-7

","original","zhKind","translation","complete",false,"ONFO","公司与财报","融资","Nasdaq","aihot","/items/kdnfefggrhvvfarspmivkt8yv","https://www.sec.gov/Archives/edgar/data/1825452/000121390026112189/0001213900-26-112189-index.htm","rss-sec-xbrl","name","SEC · EDGAR 财务披露","rss","firstParty","iconUrl","/api/img-proxy?u=https%3A%2F%2Fwww.sec.gov%2Fthemes%2Fcustom%2Fuswds_sec%2Fassets%2Fimg%2Ffavicons%2Fapple-touch-icon.png&mode=avatar&exp=1793059200&sig=baa2797e14ad5ba1","iconSrcSet","/api/img-proxy?u=https%3A%2F%2Fwww.sec.gov%2Fthemes%2Fcustom%2Fuswds_sec%2Fassets%2Fimg%2Ffavicons%2Fapple-touch-icon.png&mode=avatar-48&exp=1793059200&sig=8397742dbfd945bd 48w, /api/img-proxy?u=https%3A%2F%2Fwww.sec.gov%2Fthemes%2Fcustom%2Fuswds_sec%2Fassets%2Fimg%2Ffavicons%2Fapple-touch-icon.png&mode=avatar-96&exp=1793059200&sig=acd2a56367c2cf92 96w","changelogVersion","2026-10-01T08:00"]